

6-14-00

06/15/00
JC833 U.S. PTO

Practitioner's Docket No. 00271-US-NEW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

jc571 U.S. PTO
09/594667
06/15/00

NEW UTILITY PATENT APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): JOHN, Varghese; TUNG, Jay; HOM, Roy; GUINN, Ashley; FANG, Lawrence;
GAILUNAS, Andrea; and MAMO, Shumeye
For (title): DIPEPTIDE INHIBITORS OF β -SECRETASE

1. Type of Application

This transmittal is for an original (nonprovisional) utility application for U.S. Patent.

2. Papers Enclosed

A. Required for filing date under 37 C.F.R. 1.53(b) (Regular) or 37 C.F.R. 1.153 (Design) Application

78 Pages TOTAL of Application, including:

44 Pages of Specification
17 Pages of Claims
1 Page of abstract
0 Pages of Drawings

B. Other Papers Enclosed

3 Pages of declaration (unsigned)

CERTIFICATION UNDER 37 C.F.R. 1.10

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date June 15, 2000, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EL270711229US, addressed to the: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

J. MARK HOCH
(type or print name of person mailing paper)
J. Mark Hoch
Signature of person mailing paper

3. **Relate back**

Amend the specification by inserting, before the first line, the following sentence:
This application claims the benefit of U.S. Provisional Application No. 60/139,173, filed 6/15/1999.

4. **Declaration or Oath:** Enclosed (unsigned)

5. **Inventorship Statement:** The inventorship for all the claims in this application is the same.

6. **Language:** English

7. **Fee Calculation (37 C.F.R. 1.16)**

Regular Application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 CFR 1.16(a) \$760.00
Total Claims (37 CFR 1.16(c))	111	- 20 =	91 x	\$18.00	\$ 1638.00
Independent Claims (37 CFR 1.16(b))	3	- 3 =	0 x	\$78.00	\$ 0.00
Multiple Dependent Claim(s), if any (37 CFR 1.16(d))			+	\$260.00	\$ 0.00
Total Filing Fee:					\$ 2398.00

8. **Fee Payment**


Filing Fee enclosed. The Commissioner is hereby authorized to charge the filing fee to Deposit Account No. 01-2707. A duplicate of this paper is enclosed.

9. **Authorization to Charge Additional Fees**

The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 01-2707.

37 C.F.R. 1.17(a)(1)-(5) (extension fees pursuant to § 1.136(a))
Any deficiencies in the above filing fee.

10. Instructions as to Overpayment: Credit Account No. 01-2707.


SIGNATURE OF PRACTITIONER

Reg. No. 35,195

Tel. No.: (650) 616-5035

Customer No.: 21835

J. Mark Hoch

Elan Pharmaceuticals, Inc.

800 Gateway Blvd.

South San Francisco, CA 94080

090467 094600

Tetrapeptide Inhibitors of β -Secretase

Field of the Invention

- 5 This invention is directed to compounds useful in treatment of Alzheimer's disease and more specifically to compounds that are capable of β -secretase enzyme inhibition, thus interfering with cleavage of amyloid precursor protein to produce beta-amyloid, a major component of the amyloid plaques found in the brains of Alzheimer's sufferers.

Background of the Invention

- 10 Alzheimer's disease (AD) is a progressive degenerative disease of the brain primarily associated with aging which results in loss of memory and orientation. As the disease progresses, motor, sensory and linguistic abilities are also affected until there is global
15 impairment of multiple cognitive functions of the brain. These cognitive losses occur gradually, but typically lead to severe impairment and eventual death in the range of four to twelve years.

- Alzheimer's disease is characterized by two major pathologic observations in the brain:
20 neurofibrillary tangles and amyloid (or neuritic) plaques. Neurofibrillary tangles occur not only in Alzheimer's disease but also in other dementia-inducing disorders, while amyloid plaques are peculiar to AD. Smaller numbers of these lesions in a more restricted anatomical distribution are found in the brains of most aged humans who do not have clinical AD. Amyloidogenic plaques and vascular amyloid angiopathy also characterize
25 the brains of individuals with Trisomy 21 (Down's Syndrome) and Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D). At present, a definitive diagnosis of AD usually requires observing the aforementioned lesions in the brain tissue of patients who have died with the disease or, rarely, in small biopsied samples of brain tissue taken during an invasive neurosurgical procedure.

- 30 Neurofibrillary tangles are characterized as networks of microtubules and microfilaments which were once structural supports running symmetrically through the nerve cells that transported nutrients but have degenerated into dysfunctional tangled masses. They can be described histologically as non-membrane bound bundles containing paired, helically
35 wound filaments (PHF) that are approximately 10 nm in length and located in the

perinuclear cytoplasm of certain neurons. Major components of paired helical filaments are highly phosphorylated tau proteins (PHF-tau) of 60 kDa, 64 kDa and 68 kDa. A β peptide is also a component of these tangles. Tau belongs to the family of microtubule-associated proteins and plays a role in the microtubule assembly and stabilization. In certain other neurodegenerative disorders, including corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and Pick's disease, hyperphosphorylated tau proteins also accumulate in brain tissue in association with abnormal filaments. Recent research indicates that the pattern of hyperphosphorylation and the resulting ultrastructure of the helical filaments are somewhat different in each type of disease.

Amyloid plaques, on the other hand, are peculiar to and a defining feature of AD. Amyloid plaques are predominantly composed of amyloid beta peptide (A β , also sometimes designated as β A4). A β is derived by proteolysis of the amyloid precursor protein (APP) and is comprised of 39-43 amino acids. Several proteases called secretases are involved in the processing of APP. It appears that the abnormal processing and deposition of A β in areas of the brain responsible for cognitive activities is a major factor in the development of AD. Cleavage of APP at the N-terminus of the A β peptide by β -secretase and the C-terminus by one or more γ -secretases constitutes the amyloidogenic pathway, i.e., the pathway by which A β peptide is formed. Cleavage of APP by α -secretase and the same or a different gamma secretase produces α -sAPP, a secreted form of APP that does not result in amyloid plaque formation. This alternate pathway precludes the formation of AB. It has been proposed that A β peptide accumulates as a result of the processing of APP by β -secretase and that therefore inhibition of the activity of this enzyme is desirable for treatment of AD. See for example, *β -Amyloid and Treatment Opportunities for Alzheimer's Disease*, Sabbagh, M., et al., **Alz. Dis. Rev.** **3**, 1-19, (1997).

Several lines of evidence indicate that progressive cerebral deposition of particular amyloidogenic proteins, β -amyloid proteins, (A β), play a seminal role in the pathogenesis of AD and can precede cognitive symptoms by years or decades. See, Selkoe, *Neuron* 6:487 (1991). A β is released from neuronal cells grown in culture and is present in cerebrospinal fluid (CSF) of both normal individuals and AD patients. See, Seubert et al., *Nature* 359:325-327 (1992).

Although diffuse deposition of A β peptide occurs in most all humans with aging, the formation of amyloid plaques occur only in AD patients. Formation of these plaques is believed to occur over a period of years or even decades. The A β peptide in amyloid

5 plaques is always folded in a particular three-dimensional pattern called a beta-pleated sheet and appears to be chemically modified as well, which could explain the association of the A β peptides into the larger, denser plaques, rather than the diffuse deposits normally seen. Associated with this central core of A β peptide in the amyloid plaque are surrounding abnormal neurites and several types of altered glial cells. Glial cells normally

10 associate with neurons and perform support and protective functions. On the outside of the plaque are reactive astrocytes, which are a type of glial cell typically found in injured brain areas. Additionally many other biochemical components, including enzymes, proteoglycans and apolipoproteins are present in the plaques. For a discussion of the formation of these plaques see for example: Sabbagh, M., et al., cited supra.

15 The neurons touching the amyloid plaques are progressively debilitated and ultimately die. At present it is not known whether the A β peptide is neurotoxic in itself or if the secondary features of the amyloid plaques, e.g., the abnormal glial cells, cause the nerve cells to die. Researchers have demonstrated that the A β peptide has neurotoxic effects in

20 vitro. Still other researchers have demonstrated that the 25-35 amino acid sequence of A β peptide is similar to that of substance P, an endogenous neuropeptide compound present in certain brain tissues and having neuroexcitatory effects. Co-administration of substance P in the study blocked the neurotoxic effect of A β peptide in rats. See: *An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P*. Kowall

25 NW, et al., **Proc Natl Acad Sci USA** **88** (16) p7247-51 (1991). Another study reports that A β peptide is neurotoxic through its interference with Ca⁺⁺ homeostasis. Korotzer A.R., et al., *Differential regulation by beta-amyloid peptides of intracellular free Ca²⁺ concentration in cultured rat microglia*. **Eur. J. Pharmacol.**, **288** (2):125-30 1995..

Further, some studies have proposed that A β peptide is responsible for the

30 hyperphosphorylation of tau, a microtubule associated protein, which results in formation of PHFs and neurofibrillary tangles as described above. Thus, with A β peptide clearly linked to the formation of amyloid plaques and implicated in the formation of


neurofibrillary tangles in AD, there is a need for agents and methods for reduction of A β peptide *in vivo*.

At present there are no published means for specifically inhibiting the β -secretase enzyme, or even structural identification of the β -secretase enzyme is or a peptide sequence of its active site. However, a commonly assigned application naming John Anderson, Guriqbal Basi, et al. as inventors and entitled: β -Secretase Enzyme Compositions and Methods, identifies the enzyme and methods of use thereof. Additionally, a commonly assigned application naming Varghese John, Jay Tung, Roy Hom and Larry Fang as inventors and entitled: Dipeptide Inhibitors of β -Secretase, describes and claims dipeptide inhibitors of the β -secretase enzyme. The two above-identified applications are being filed on the same day as the present application. The contents of these co-pending applications are hereby incorporated by reference in their entirety for all purposes. Additionally, US 4 636 491 to Bock, et al. discloses certain tetrapeptides having renin inhibitory activity. Some of the compounds disclosed in the broadest Markush description by Bock encompass some of the compounds of the present invention. However, all the specific examples of Bock are directed to the sequence: Phe-His-Sta-Leu or to the same sequence containing derivatives of statine. The sequence is neither claimed, nor operative in the β -secretase inhibition disclosed herein. It is believed that the compounds claimed herein are patentable as a selected subgenus of the broad Markush disclosure of Bock.

Detailed Description of the Invention

This invention is directed to the discovery of a class of compounds that inhibit β -amyloid peptide production by preferentially binding to and inhibiting the proteolytic function of the β -secretase enzyme. Inhibition of β -secretase enzyme stops or reduces the production of A β from APP and thus reduces or eliminates the formation of amyloid plaques and other types of A β deposition in the brain. Therefore, the compounds are useful in the prevention of Alzheimer's Disease in patients susceptible to AD and/or in the treatment of patients with AD in order to inhibit further deterioration in their condition. Now it has been discovered that the compounds of the present invention provide inhibitors of the β -secretase enzyme.

The invention relates to compounds of formula 1




Formula 1

5

wherein

A is a straight or branched chain alkanoxy or alkenoxy of 1 to 5 carbon atoms, aryl, arylalkyl, the aryl being optionally substituted with 1 to 2 carbon atoms or halogen, adamantyloxy, or 4-aminobutanoic acid;

10 B is selected from the group consisting of hydroxy,



wherein a dithered line represents a point of attachment at B of formula 1;

D is H or an oxo group;

L is a 5 or 6 membered saturated, unsaturated or aromatic heterocycle having from 1 to 3

15 heteroatoms chosen from nitrogen, oxygen or sulfur, or a saturated, unsaturated or aromatic carbocycle of 3 to 6 carbon atoms, any group represented by L having optional substitution with R', OR', or halogen;

Q is a bond, or is a straight chain linking group of 1 to 3 non-hydrogen atoms chosen from the group consisting of $-\text{CH}_2-$, $-\text{O}-$, and $-\text{NH}-$ wherein O and N may not be adjacent;

ring M is a stable 5 to 7-membered saturated, unsaturated or aromatic heterocycle having up to 2 additional N atoms and optionally having 1 to 2 atoms of O and S,

T is independently selected from the group consisting of H, OH, NO_2 , $\text{C}(\text{O})\text{N}(\text{R})_2$, F, C_1 - C_3 alkoxy, hydroxymethyl and CF_3 , wherein at least one T is other than H;

x is an integer of 1 to 3,

y is an integer of 1 to 6,

z is 0 (zero), 1 or 2,

R' is independently H, $-\text{OH}$, C_1 - C_2 alkyl or phenyl,

R is independently H, C_1 - C_4 alkyl, or phenyl,

and E is H, or C_1 - C_2 alkyl;

R_1 is C_1 - C_5 alkyl;

R_2 is 2-propyl, 2-methylpropyl- or phenyl optionally substituted with R', OR' or halogen;

R_3 is phenyl, C_1 - C_5 alkyl, or 1-(2-methylthio-)ethyl-;

R_4 is 2-propyl, 2-butyl or 2-methylpropyl;

and stereoisomers, hydrates or pharmaceutically acceptable salts or esters thereof to

reduce the formation of A β peptide.

Still further, it is an object of the present invention to provide pharmaceutical compositions containing such β -secretase inhibitors in a pharmaceutically acceptable carrier. Other objects of the invention will become apparent from reading the specification and appended claims.

Detailed Description of the Invention

Natural amino acids are available in abundance, and a great array of non-naturally occurring amino acids have been prepared by techniques well known to those skilled in the art of organic synthesis. Roberts and Vellaccio provide a comprehensive listing of non-natural amino acids, and techniques for the synthesis of many variations thereof in *The Peptides*, Vol. 5: Analysis, Synthesis, Biology; Academic Press, NY 1983. A more recent description of additional routes to chirally pure non-natural amino acids is in: *Asymmetric*

synthesis of α -amino acids from carbohydrates as chiral templates; Cintas, P.

Tetrahedron, **47** (32), 6079-111 (1991). Thus one skilled in the art can synthesize the amino acid precursors used in the preparation of the compounds of the invention by a judicious selection of one or more of the methods outlined above, which articles are
5 hereby incorporated by reference.

Statine is a non-standard amino acid residue present in pepstatin that provides this peptide its inhibitory activity (Rich, D.H., *J. Med. Chem.* **28**, p. 262 (1985). Interestingly, pepstatin has no inhibitory activity in assays with β -secretase. Statine has the chemical
10 name (3S, 4S)-4-amino-3-hydroxy-6-methylheptanoic acid, and is further identified in the Merck Index (11th ed.) at monograph no. 8759, and is available commercially, such as through the Sigma-Aldrich catalog. The three letter abbreviation given to statine in the peptide art is Sta. The (3S, 4S) stereoisomer is designated Sta(s) or statine(s). Statine derivatives are also well known in the literature and can be prepared by methods
15 disclosed in United States Patent 4,397,786. Other methods are described in the series cited above (The Peptides, Vol. 5: Analysis, Synthesis, Biology; Academic Press, NY 1983] and by Bringmann et al. in Synlett (5), pp. 253-255 (1990); by Kessler and Schudok in Synthesis (6) pp. 457-8 (1990); and by Nishi and Morisawa in Heterocycles 29(9), 1835-42 (1989).

20 Unless defined otherwise, all scientific and technical terms used herein have the same meaning as commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are hereby incorporated by reference in their entirety for all purposes.

25 Optical Isomers-Diastereomers-Geometric Isomers

Some of the compounds described herein contain one of more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisometric forms which
30 may be defined in terms of absolute stereochemistry as (R)- or (S)-, or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible diastereomers and enantiomers as well as their racemic and optically pure forms. Optically active (R)- and (S), or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described

herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are intended to be included.

5 Stereoisomers refer to molecules wherein the same atoms attach to one other in the same order, but the positioning of the attachment varies so that two molecules may not be spatially identical; they are classified according to the number and symmetry of the chiral centers in each molecule. Chiral centers are atoms to which the same kinds of atoms are attached but have more than one possibility for arrangement around the chiral center
10 atom. There are two types of stereoisomers: diastereomers and enantiomers.

Diastereomers are two molecules which are stereoisomers that have the same connectivity but are not mirror images of each other. Chiral centers in diastereomers are arranged so that an internal plane of symmetry exists in the molecule. The chemical and physical
15 properties of diastereomers tend to differ because different spatial shape changes the ways in which the molecules interact.

Enantiomers are two molecules which are exact mirror images of one other, because each chiral center is a reflection of the chiral center of the other enantiomer. Enantiomers
20 have identical chemical and physical properties, which make separations based on their physical properties extremely difficult. Enantiomers are usually labeled R and S (for right-handed and left-handed) to distinguish them.

Racemic mixtures are defined as mixtures of two mirror image forms of the same
25 molecule (enantiomers) in equal amounts.

Although stereoisomers may not vary greatly on a chemical level, on the biological level, different stereoisomers isomers "fit" differently into the various protein receptors that drive biochemical processes and thus stereoisomers, and frequently even enantiomers, do
30 not bind equally. Therefore, enantiomers of the same compound can have different effects within the human body.

Many of the embodiments of the present invention embrace the residue -or side chain- of a naturally occurring α -amino acid, it is to be noted that each α -amino acid has a
35 characteristic "R-group", the R-group being the residue -or side chain- attached to the α -

carbon atom of the amino acid. For example, the residue of glycine is H, for alanine it is methyl, for valine it is 2-propyl, for methionine it is methylthioethyl. The specific residues of the naturally occurring α -amino acids are well known to those of skill in the art. See, e.g., A. L. Lehninger, Biochemistry: The Molecular Basis of Cell Structure and Function, 1975 (or any edition thereafter), Worth Publishers, NY, see, particularly Chapter 4). As used herein, the residues of naturally occurring α -amino acids are the residues of those about twenty α -amino acids found in nature which are incorporated into a protein by the specific recognition of the tRNA molecule with its cognate mRNA codon in humans.

Those non-naturally occurring α -amino acid residues embraced by the present invention are known to those of skill in the art. Statine, as discussed above in the background of the art is a commercially available γ -amino acid. In the compounds herein the preferred stereoisomer is the S configuration and the absolute stereochemistry is (3S, 4S).

Other modified or non-usual amino acids are 2-aminobutyric acid (Abu) and phenylglycine (Phg). In amino acids of this type a change is made in the side chain of the amino acid, usually by varying the length or substitution thereon. For instance, 2-aminobutyric acid is an α -amino acid that varies from valine by the removal of one of the methyl groups from the side chain. Phenylglycine is a homolog of the naturally-occurring amino acid phenylalanine, which lacks the methylene linkage between the peptide backbone and the phenyl group found in phenylalanine. Norleucine (Nle) is a slightly different example where the branching methyl group of leucine is shifted rather than deleted to make a non-branching (normal) chain having the same number of carbon atoms as leucine. These unusual amino acids can be incorporated into peptide chains using the standard peptide linkage synthetic procedures described below for the naturally-occurring amino acids.

As used herein, the term "alkyl" includes the straight, branched-chain and hydrocarbons, the number of carbons atoms being generally specified. Where not specified the alkyl groups preferably contain from about 1 up to about 12, more preferably 1 to 6, and most preferably 1 to 5 carbons. Exemplary of such moieties are methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, sec-butyl, pentyl, n-hexyl, n-nonyl, n-decyl, and the like. The

term "lower alkyl " includes C₁ –C₅ alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl, n-pentyl, and the like.

5 As used herein, "heteroatom(s)" is/are selected from O, N or S, unless otherwise specified.

Alkenes are alkyl groups containing at least one C-C double bond (-C=C-). Exemplary of alkenyl moieties are 2-methyl-2-propenyl, 2-methyl-1-propenyl, propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2,2-difluoroethenyl, as well as those straight and branched chained
10 moieties having more than one double bond.

The term "lower alkyl " includes C₁ –C₅ alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl, n-pentyl, and the like.

15 The term "halo" and "halogen" refer to chloro, bromo, fluoro, and iodo.

"Lower alkenyl" refers to those C₂ -C₆ unsaturated groups such as vinyl, 1-propene-2-yl, 1-butene-4-yl, 1-pentene-5-yl, 2-methyl-2-butene-4-yl and the like.

20 The term "alkanoxy" refers to those groups having an alkyl moiety from 1 to 6 carbon atoms linked to an oxygen atom. This oxygen is linked to the carbon atom of another group. Examples of alkanoxy groups are: methoxy, ethoxy, propoxy, butoxy, iso-butoxy, and the like.

25 The term "alkenoxy" includes C₂ –C₆ groups having a C-C double bond and an oxygen atom, such as ethenyloxy, propenyloxy, iso-butoxyethenyl and the like.

The term "amine" includes primary, secondary and tertiary amine which may be in straight or branched chains or, in the case of secondary and tertiary amines within rings,
30 and are optionally substituted with, C₁ -C₇ acyloxy, C₁ -C₆ alkyl, C₁ -C₆ alkoxy, nitro, carboxy, carbamoyl, carbanoyloxy, cyano halogen, amino and the like.

The terms "carboxyl", "carboxylate" and "carbamoyl" are all terms referring to functional groups containing the a carbon atom double bonded to an oxygen as well as single
35 bonded to another oxygen, in the case of carbamoyl the carbon is additionally bonded to a nitrogen atom. These terms all include the corresponding pharmaceutically acceptable C₁ -C₆ alkyl and aryl esters.

The term "aryl" includes 3 to 8 membered stable saturated or unsaturated organic monocyclic rings having 0 to 4 hetero atoms selected from S, O, and N; and 7 to 10 membered organic stable, saturated or unsaturated, bicyclic rings having 0 to 5 hetero atoms selected from S, O, N; both of which may be substituted by halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₁-C₆ alkyl, C₁-C₆ substituted alkoxy, substituted C₂-C₆ alkenyl, or substituted C₂-C₆ alkynyl, hydroxy, amino, nitro, cyano, carboxy, hydroxymethyl, aminomethyl, carboxymethyl, C₁-C₄ alkylthio, C₁-C₄ alkanoyloxy, carbamoyl, or halo-substituted C₁-C₆ alkyl. The term "aryl" also includes fused ring carbocyclic and heterocyclic moieties having at least one aromatic nucleus. The term "arylalkyl" refers to any of the above aryl groups also having an alkyl radical through which the group connects to the larger structure. Preferred aryl and aralkyl moieties are phenyl, benzyl, phenethyl, 1- and 2-naphthyl, naphthylmethyl, 5-, 6-, 7-, and 8-quinolinyl, benzofuryl, indenyl, or indanyl, benzimidazolyl, indolyl, benzothiophenyl, indole-3-ethyl and 5-, 6-, 7-, and 8-tetrahydroisoquinoline. Other examples of such ring systems may be found in J. Fletcher, O. Dermer, R. Fox, Nomenclature of Organic Compounds, pp. 20-63 (1974), and in the Examples herein.

The terms substituted alkyl, substituted alkenyl, substituted alkynyl and substituted alkoxy are these radicals substituted with halogen, hydroxy, amino, C₁-C₇ acyloxy, nitro, carboxy, carbamoyl, carbamoyloxy, cyano, or C₁-C₆ alkoxy, and may be substituted one or more times with the same or a different group, preferably substituted 1 to 3 times.

A linking group is defined as a divalent linear chain facilitating the reach of a binding group, for example a carboxyl group to binding sites within the target enzyme. The facilitation occurs as a result of either or both the extension of the group at a particularly advantageous distance from another binding site on the molecule or in providing an advantageous flexibility to the group in being able to adopt a conformation that allows for optimal binding. Particular examples of the group Q which may be present in compounds of the invention include groups of formula: -CH₂-(CH₂)_n-; -O-(CH₂)_n-; NH-(CH₂)_n-; -O-CH₂-O-; -O-CH₂-NH-; NH-CH₂-NH- wherein n=0, 1 or 2.

A pharmaceutically acceptable salt is any salt which substantially retains the activity of the parent compound and does not impart any deleterious or undesirable effect on the

subject to whom it is administered and in the context in which it is administered. Such salts are those formed with pharmaceutically acceptable cations, e.g., alkali metals, alkali earth metals, etc. A pharmaceutically acceptable ester is any ester formed on a parent carboxylic acid which substantially retains the activity of the parent compound and does not impart any deleterious or undesirable effect on the subject to whom it is administered and in the context in which it is administered. A pharmaceutically acceptable excipient or diluent is any excipient which retains the activity of the therapeutic compound with which it is admixed and does not impart any deleterious or undesirable effect on the subject to whom it is administered and in the context in which it is administered.

Abbreviations used in this specification represent the following:

Ac= acetyl (methylcarbonyl)

bd = broad doublet

BOC=tert-butoxycarbonyl

bs = broad singlet

CBZ=benzyloxycarbonyl

d = doublet

DMF = dimethylformamide

EDC = ethyl-1-(3-dimethylaminopropyl)carbodiimide

EtOAc = ethyl acetate

eq. = equivalents

HOBt = 1-hydroxybenzotriazole

IC₅₀ = inhibitory concentration of a compound where the enzyme activity is reduced by half.

m = multiplet

mass. spec. or MS= mass spectrum

nmr = nuclear magnetic resonance spectrum

R_f = ratio of movement of a substance on a thin layer chromatogram in comparison to the movement of the solvent front.

s = singlet

t = triplet

TEA = triethylacetate

TFA = trifluoroacetic acid

THF = tetrahydrofuran

TLC = thin layer chromatography

δ = units of measurement for nuclear magnetic resonance spectroscopy which are relative to a standard, e.g. trimethyl silane.

μL = microliter

μM = micromolar (an expression of concentration in micromoles/ liter)


The terms N-terminal or N-terminus refer to that terminal or end group of a peptide bearing the free or derivatized amino group of an amino acid residue. Likewise, C-terminal or C-terminus refers to that terminal or end group of a peptide bearing the free or

derivatized carboxy group of an amino acid residue. The term "capping group" refers to a non-amino acid moiety bonded to the C- or N-terminal of the peptide chain. Examples of N-terminal capping groups used in peptide synthesis are BOC (t-butoxycarbonyl) and CBZ (benzyloxycarbonyl) and glutamic acid. Other capping groups are acetyl and adamantyloxycarbonyl. Non-limiting examples of are shown in Table 1.

Methods of Synthesis

Reaction scheme 1 illustrates the construction of some of the peptides provided herein and the variety of reactions that may be used to prepare intermediates from which compounds for formula 1 may be prepared, and provides a generic method for the synthesis of the tetrapeptides. Although statine and valine are employed as the N-terminal amino acids. It is to be understood that other peptides may be also be substituted in place of valine and that derivatives of statine may be employed as alternatives in the steps below to provide further tetrapeptides as provided herein.

Scheme 1



This scheme may be varied as desired by selecting a different carboxy protected amino acid residue, for example, α -amino-butyric acid (Abu) or phenylglycine (Phg) in Step A to couple with statine. Or alternatively, selecting a different statine derivative, such as Phe-Sta, wherein the 2-methyl-propyl group is replaced by benzyl, to be coupled with the starting amino acid in Step A. Derivatives of statine are known in the art and described in United States Patent 4,397,786.

Experimental Methods

Step A: Coupling of the C-terminal amino acid with statine.

Boc-Sta(s) (1.0 equiv.) was dissolved in 30 mL of dry dichloromethane, then HOBt (2.0 equiv.), H₂N-Val-OBzl .HCl (1.0 equiv.) and TEA (5 equiv.) were added and the mixture was stirred for 20 minutes. EDC (1.2 equiv.) was then added and allowed to stir overnight under an atmosphere of nitrogen. The reaction was diluted with water and extracted with EtOAc (3x). The organic layers were washed with aqueous citric acid (2x), sat. NaHCO₃ (2x), brine, then dried with MgSO₄.

Step B: Removal of the Boc-protecting group from the resulting dipeptide.

The Boc-protecting group of the dipeptide was dissolved in a trifluoroacetic acid/methylene chloride (1/1) solution. The reaction was monitored by TLC to confirm the consumption of starting material at which time the solvents were removed under vacuum to yield the free amine which was used without further purification.

Step C: Coupling deprotected amine with a selected amino acid residue (AA₁).

Boc-AA₁-OH (1.0 equiv.) is dissolved in 30 mL of dry dichloromethane, then HOBt (2.0 equiv.), H₂N-Stat-Val-OBzl .HCl (1.0 equiv.) and TEA (5 equiv.) were added and all was stirred for 20 minutes. EDC (1.2 equiv.) is added and the mixture is stirred overnight under an atmosphere of nitrogen. The reaction is then diluted with water and extracted with EtOAc (3x). The organic layers are washed with aqueous citric acid (2x), sat. NaHCO₃ (2x), brine, then dried over MgSO₄.

Removal of the Boc-protecting group from the resulting tripeptide is accomplished as in Step B above.

Step D: Coupling of the tripeptide with a selected amino acid residue (AA₂).

R-AA₂-OH (1.0 equiv.) is dissolved in 30 mL of dry dichloromethane, then HOBT (2.0 equiv.), H₂N-AA₁-Stat-Val-OBzl.HCl (1.0 equiv.) and TEA (5 equiv.) are added and the reaction mixture is stirred for 20 minutes. EDC (1.2 equiv.) is then added to the mixture and is allowed to stir overnight under an atmosphere of nitrogen. The reaction is diluted with water and extracted with EtOAc (3x). The organic layers are washed with aqueous citric acid (2x), sat. NaHCO₃ (2x), brine, then dried over MgSO₄.

Step E: Removal of the Carboxybenzyl (Cbz) protecting group from the C-terminus

R-AA₂-AA₁-Stat-Val-OBz (1.2 g) is dissolved in 100 ml of MeOH and Pd/C (1g, 10%) is added. The reaction is subjected to a hydrogen gas atmosphere of 50psi for 2 hours. The resulting slurry is filtered through a pad of celite, and rotoevaporated to yield the desired material.

Step F: Coupling of the C-terminal end of the tetrapeptide with a functionalized amine

R-AA₂-AA₁-Stat-Val-OH (1.0 equiv.) is dissolved in 30 mL of dry dichloromethane, then HOBT (2.0 equiv.), H₂N-R (1.0 equiv.) and TEA (5 equiv.) were added and the reaction mixture is stirred for 20 minutes. EDC (1.2 equiv.) is added and allowed to stir overnight under an atmosphere of nitrogen. The reaction is diluted with water and extracted with EtOAc (3x). The organic layers are washed with aqueous citric acid (2x), sat. NaHCO₃ (2x), brine, then dried over MgSO₄.

The amine groups (R-NH₂) of the examples shown below are commercially available unless otherwise indicated by reference to a citation in a journal. Some of the compounds are supplied as the methyl ester, if a carboxylic acid function is present. If only the free carboxylic acid group is available commercially, the methyl ester can be prepared as indicated in step H below.

Step G: Cleavage of the C-terminal capping group methyl ester to provide free carboxylic acid or carboxylate salt

The methyl ester (1 equiv.) is dissolved in a suitable solvent (MeOH/water, dioxane/water, or THF/water). Hydroxide (2-20 equiv., KOH, NaOH, or LiOH) is added and the reaction mixture is allowed to stir until the all of the ester is converted to acid as evidenced by TLC. Volatile solvents are removed and the reaction is acidified with citric

acid. The resulting precipitate is collected and characterized to insure the desired material is obtained.

Step H: Preparation of the methyl ester for the C-terminal capping reaction

5 The selected acid is dissolved in dry methanol. HCL (gas) is bubbled through the mixture for 5 minutes. The reaction is then stirred overnight and rotoevaporated to yield the desired methyl ester.

Step J: Aminoaryl diesters to Aminocyclohexyl diesters

10 An example of this ring hydrogenation is with dimethyl –aminophthalate. The amino-phthalate in acetic acid (12%v/v) was added 1.25 g of 5% rhodium on alumina (50% w/w), the mixed slurry was saturated with hydrogen at 55 PSI and shaken for a total of 72 hrs. Upon completion of the hydrogenation the reaction was filtered through Celite and
15 dried over anhydrous sodium sulfate. Filtration and subsequent rotoevaporation yielded crude product, which was then subjected to silica gel chromatographic purification to provide dimethyl aminocyclohexyldicarboxylate as a pale white solid. See also: Fieser & Fieser, Reagents for Org. Syn. 4, 418 and Freifelder, M.; Ng, Y. H.; Helgren, P. F.; *J. Org. Chem.*, 30, 2485-6.

Step K: Formation of azide

20 The Halide (5.5 mmole) was dissolved in dry DMF and sodium azide (6.88 mmole) was added. The reaction was stirred overnight under nitrogen at 40⁰ C. Workup: the reaction
25 was concentrated under vacuum and partitioned between ethyl acetate and water. The organic layer was dried by MgSO₄. The azide product was obtained in 89 % yield.

Step L: Reduction of Azide

30 The azide (2.44 mmole) was dissolved in THF, and PtO₂ (catalytic amount). The reaction was shaken on a Parr shaker in the presence of hydrogen (20-30 psi) for one hour. Workup: Filtered through celite and was rinsed with methanol. The filtrate was concentrated down to obtain the desired amine product in 92% yield.

Step M: Protection of amine

35 The amine (9.9 mmole) and triethylamine (9.9mole) was dissolved in dry dichloromethane and (Boc)₂O was added. The reaction was stirred overnight under

nitrogen. Workup: the reaction was concentrated on a rotary evaporator and the residue was taken up with ethyl acetate and then washed with water, citric acid, sodium bicarbonate, and brine. The organic solvent was dried over MgSO_4 (86%).


5 Step N: N-methylation

The amine (4.1 mmole) was dissolved in THF and methyl iodide was added, followed by sodium hydride. The reaction was stirred overnight under nitrogen. Workup: the reaction was concentrated on a rotary evaporator and the residue was taken up with ethyl acetate and then washed with water, citric acid, sodium bicarbonate, and brine. The organic solvent was dried over MgSO_4 .

Step O: Bromination

15 The methyl ester (26.9 mmole), benzoyl peroxide (0.455 mmole), and NBS (26.9 mmole) were dissolved in benzene and kept at reflux overnight under N_2 , after which the solution was concentrated to dryness. The remaining solid was filtered and washed with hot water, then dried on high vacuum overnight (81%).

20 Steps K, L and O are employed in the order set forth below:



Mixtures of final products or intermediates obtained can be separated on the basis of the physico-chemical differences of the constituents, in known manner, into the pure final products or intermediates, for example by chromatography, distillation, fractional crystallization, or by formation of a salt if appropriate or possible under the circumstances.

For the purpose of classification of the inhibitor activities of the compounds of the present invention, the Examples given below have been grouped by their IC₅₀ concentrations.


Those compounds of Group IV have an IC₅₀ of greater than 200 μM. The compounds of

- 5 Group III have an IC₅₀ concentration of from between 100 μM and 200 μM and are the preferred compounds of the invention. The compounds of Group II have an IC₅₀ concentration of from between 10 μM and 99 μM and are the more preferred compounds of the invention. The compounds of Group I have an IC₅₀ concentration of < 10 μM and are the most preferred compounds of the invention.

10

Table 1









Enzyme inhibition assay results for structures having the peptide backbone:





















In Examples 1-26: R₂ is 2-methylpropyl, R₃ is methylthioethyl and A is tert-butyloxycarbonyl.






15

Example	IC ₅₀ Group	B
1	IV	—OMe
2	III	—OH
3	IV	
Example	IC ₅₀ Group	B
4	IV	
5	III	

6	II	
7	III	
8	II	
9	II	
10	II	
11	I	
12	III	
13	I	

Example	IC ₅₀ Group	B
14	I	
15	I	
16	IV	
17	II	
18	II	
19	III	
20	II	
21	II	
22	III	

R	IC ₅₀ Group	B
23	III	
24	III	
25	II	
26	I	
27	II	
28	I	
29	II	
30	I	
31	II	

R	IC ₅₀ Group	B
32	I	
33	no data	
34	I	
35	II	
36	I	

**Table 1 continued for variations of amino acid substituents
and/or N-terminal capping groups.**

R	IC ₅₀ Group	Structure
37	I	R ₂ is benzyl, R ₃ is phenyl, A is acetyl and B is 4- aminomethyl-benzoic acid
38	II	R ₂ is 2-methylpropyl, R ₃ is phenyl, A is benzyloxy- carbonyl and B is 4-amino- methyl-benzoic acid

R	IC ₅₀ Group	Structure
39	II	R ₂ is 2-methylpropyl, R ₃ is phenyl, A is butyloxy-carbonyl and B is 4-amino-methylbenzoic acid

- The following non-limiting examples describe a method by which each of the compounds of Table 1 and as numbered therein were prepared following the procedure outlined
- 5 generally in Scheme 1.

Example 1

- Steps A through F were employed, substituting H₂N-Val-OMe (the methyl ester) for the
- 10 benzyloxycarbonyl protected starting material, and selecting L-Met as AA₁ and L-Val as AA₂.

Molecular Formula	C ₂₉ H ₅₄ N ₄ O ₈ S
Molecular Weight	618.87
H-nmr (solvent)	(CDCl ₃) δ 7.43(d, 1H); 7.20(d, 1H); 5.99(d, 1H); 5.20(d, 1H); 4.50(m, 1H); 3.90-3.80(m, 1H); 3.66(s, 3H); 2.50-2.30(m, 6H); 2.1-1.90(m, 6H); 1.56(m, 2H); 1.44(s, 9H); 0.99(m, 18H)
C-nmr (solvent)	(CDCl ₃) δ 190.067, 172.229, 168.561, 117.913, 70.817, 70.574, 60.181, 57.383, 52.124, 40.916, 40.234, 30.123, 128.187, 24.778, 23.022, 21.706, 19.119, 18.978, 17.802, 15.169
Mass spec (MH ⁺)	619.2

Example 2

- The product of Example 1 was further subjected to Step G to remove the methyl ester,
- 15 leaving the free C-terminal acid.

Molecular Formula	C ₂₈ H ₅₂ N ₄ O ₈ S
Molecular Weight	604.80
H-nmr (solvent)	(CD ₃ OD) δ 8.33(d, 1H); 7.00(d, 1H); 4.55(m, 1H); 4.33(d, 2H); 4.1-3.8(m, 4H); 2.50(m, 2H); 2.42(d, 2H); 2.10(m, 2H); 2.08(s, 2H); 2.00(s, 3H); 1.55(m, 3H); 1.44(s, 9H); 1.33(m, 1H); 0.99(m, 18H)

C-nmr (solvent)	(CD ₃ OD) δ 194.624, 174.332, 173.972, 100.478, 71.737, 71.612, 59.118, 54.142, 52.699, 41.727, 41.256, 31.741, 31.498, 31.130, 28.716, 26.012, 25.824, 23.755, 22.563, 22.164, 20.667, 19.781, 19.540, 18.574, 18.261
Mass spec (MH ⁺)	605

Example 3

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using benzylamine as RNH₂ in step F.

Molecular Formula	C ₃₅ H ₅₉ N ₅ O ₇ S
Molecular Weight	693.91
H-nmr (solvent)	(DMSO-d) δ 7.88(d, 1H); 7.77(d, 1H); 7.41(d, 1H); 7.34(m, 5H); 6.88(d, 1H); 4.88(d, 1H); 4.45(m, 1H); 4.36(d, 2H); 3.88(m, 2H); 3.45(s, 2H); 2.44(m, 2H); 2.22(m, 2H); 2.10(s, 3H); 1.9-1.80(m, 2H); 1.50(m, 3H); 1.44(s, 9H); 1.38(m, 1H); 0.98(m, 18H)
C-nmr (solvent)	(DMSO-d) δ 172.190, 171.846, 171.665, 140.236, 128.864, 127.915, 127.359, 78.734, 58.474, 51.224, 42.642, 32.617, 30.760, 30.070, 28.714, 24.748, 23.816, 22.287, 19.763, 18.674, 18.447, 15.194
Mass spec (MH ⁺)	694

5

Example 4

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using 1-pentanamine as RNH₂ in step F.

Molecular Formula	C ₃₃ H ₆₃ N ₅ O ₇ S
Molecular Weight	673.95
H-nmr (solvent)	(DMSO-d) δ 7.89(d, 1H); 7.66(d, 1H); 7.44(d, 1H); 6.88(d, 1H); 4.88(d, 1H); 4.45(m, 1H); 3.78(m, 2H); 3.1-3.0(m, 2H); 2.50(m, 2H); 2.22(d, 1H); 2.04(s, 3H); 2.0-1.80(m, 2H); 1.55(m, 3H); 1.44(s, 9H); 1.32(t, 3H); 0.98(m, 18H)
C-nmr (solvent)	(DMSO-d) δ 187.944, 183.453, 171.657, 164.00, 156.194, 117.413, 114.615, 117.413, 114.615, 100.429, 61.405, 58.435, 51.169, 32.656, 30.830, 30.054, 29.216, 29.106, 28.714, 24.748, 23.831, 22.303, 19.209, 18.494, 15.178, 14.371
Mass spec (MH ⁺)	674

10 **Example 5**

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using ethylamine as RNH₂ in step F.

Molecular Formula	C ₃₀ H ₅₇ N ₆ O ₇ S
-------------------	---

Molecular Weight	631.87
H-nmr (solvent)	(CDCl ₃) δ 7.66(bs,1); 7.44(bs,1H); 7.20(s, 1H); 7.10(bs, 1H); 5.20(bs, 1H); 4.55(bs, 1H); 4.1-3.9(m, 5H); 3.66(s, 1H); 3.4-3.20(m, 2H); 2.6-2.40(m, 5H); 2.20-1.99(m, 5H); 1.66(bs, 1H); 1.44(d, 9H); 1.40(s, 1H); 1.20(m, 3H); 0.99(m, 18H)
C-nmr (solvent)	(CDCl ₃) δ 200.280; 190.067; 172.589; 172.001; 152.799; 149.272; 59.758; 34.246; 30.233; 29.567; 28.219; 24.739; 22.967; 21.909; 19.292; 19.022; 17.826; 15.185; 14.628
Mass spec (MH ⁺)	632.2

Example 6

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 4-aminobutanoate as RNH₂ in step F.

Molecular Formula	C ₃₃ H ₆₁ N ₅ O ₉ S
Molecular Weight	703.93
H-nmr (solvent)	(DMSO-d) δ 4.88(d, 1H); 4.44(m, 1H); 4.11(m, 2H); 3.88(m, 3H); 3.66(s, 3H); 3.44(d, 2H); 3.10(m, 2H); 2.43(m, 1H); 2.25(t, 2H); 2.14(d, 2H); 2.04(s, 3H); 1.88(m, 2H); 1.60(t, 2H); 1.44(s, 9H); 1.40(m, 1H); 0.98(m, 18H)
C-nmr (solvent)	(DMSO-d) δ 173.821, 172.089, 171.657, 78.750, 60.417, 58.456, 52.367, 51.757, 51.091, 32.617, 31.277, 30.728, 30.619, 30.078, 28.714, 24.983, 24.756, 23.784, 22.303, 19.724, 19.693, 18.674, 18.494, 15.478
Mass spec (MH ⁺)	704

5

Example 7

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 3-aminopropanoate as RNH₂ in step F.

Molecular Formula	C ₃₂ H ₅₉ N ₅ O ₉ S
Molecular Weight	689.91
H-nmr (solvent)	(DMSO-d) δ 8.11(d, 1H); 7.98(d, 1H); 7.66(d, 1H); 7.55(d, 1H); 6.88(d, 1H); 4.88(d, 1H); 4.43(m, 1H); 4.14(m, 1H); 3.77(m, 3H); 3.66(s, 3H); 2.55(m, 4H); 2.54(m, 2H); 2.21(d, 2H); 2.01(s, 3H); 1.89(m, 2H); 1.45(m, 1H); 1.44(s, 9H); 1.33(m, 1H); 0.98(m, 18H)
C-nmr (solvent)	(DMSO-d) δ 205.602, 177.567, 172.747, 171.634, 114.615, 100.421, 78.750, 59.790, 58.348, 51.867, 51.108, 35.282, 34.099, 30.799, 30.070, 28.714, 23.855, 22.721, 19.732, 19.622, 18.721, 18.462, 18.313, 15.186
Mass spec (MH ⁺)	689.9

10 **Example 8**

The product of Example 6 was further subjected to Step G to remove the methyl ester, leaving the free C-terminal acid.

Molecular Formula	C ₃₂ H ₆₉ N ₅ O ₉ S
Molecular Weight	689.91
H-nmr (solvent)	(CD ₃ OD) δ 4.56(m, 1H), 4.20(m, 1H); 4.01-3.98(m, 2H); 3.32(m, 2H); 2.50(m, 2H); 2.24(m, 2H); 2.10(m, 3H); 2.00(m, 4H); 1.88(t, 2H); 1.55(m, 1H); 1.44(s, 9H); 1.44(s, 9H); 1.34(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(CD ₃ OD) δ 173.682, 74.206, 71.408, 54.463, 43.827, 41.444, 39.752, 32.188, 31.397, 31.185, 28.716, 25.730, 23.598, 22.305, 20.635, 19.656, 18.605, 18.206, 15.235
Mass spec (MH ⁺)	690.1

Example 9

- 5 The product of Example 7 was further subjected to Step G to remove the methyl ester leaving the free C-terminal acid.

Molecular Formula	C ₃₁ H ₅₇ N ₅ O ₉ S
Molecular Weight	675.89
H-nmr (solvent)	(CD ₃ OD) δ 4.45(m, 1H); 4.1-4.0(m, 2H); 4.0-3.98(m, 3H); 3.54(m, 2H); 2.56(m, 3H); 2.40(m, 2H); 2.1-2.0(m, 4H); 1.66(m, 2H); 1.44(m, 11H); 1.22(t, 2H); 0.98(m, 18H)
C-nmr (solvent)	(CD ₃ OD) δ 174.231, 173.666, 100.478, 74.167, 71.392, 43.804, 41.562, 36.413, 34.547, 32.627, 31.444, 31.185, 30.856, 28.724, 25.855, 23.622, 22.266, 19.758, 15.259
Mass spec (MH ⁺)	676

Example 10

- Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 2-aminomethylthiazole-5-carboxylate as RNH₂ in step F and then removal of the methyl ester according to step G. The methyl 2-aminomethylthiazole-5-carboxylate was prepared according to Synthesis 1986, page 992.

Molecular Formula	C ₃₃ H ₅₆ N ₆ O ₉ S
Molecular Weight	744.98
H-nmr (solvent)	(CD ₃ OD) δ 9.10(m, 1H); 8.88(m, 1H); 8.26(s, 1H); 7.55(m, 1H); 4.78(m, 2H); 4.65(m, 1H); 4.33(m, 2H); 4.1-3.9(m, 3H); 3.33(2H); 2.50-2.10(m, 4H); 2.10-1.90(m, 4H); 1.60(m, 1H); 1.44(m, 10H); 1.30(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(CD ₃ OD) δ 168.351, 123.778, 65.278, 54.203, 26.316, 25.603, 25.164, 24.827, 22.810, 22.672, 21.810, 19.780, 17.664, 16.229, 16.127, 13.593, 12.499, 12.224, 11.981, 9.99
Mass spec (MH ⁺)	745.2

Example 11

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 4-aminomethylbenzoate as RNH₂ in step F and then removal of the methyl ester according to step G.

Molecular Formula	C ₃₆ H ₅₉ N ₅ O ₉ S
Molecular Weight	737.96
H-nmr (solvent)	(MeOD) δ 8.88(m, 1H); 7.889d, 2H); 7.44(d, 2H); 4.55(m, 2H); 4.22(m, 1H); 4.0-3.9(m, 2H); 2.5-2.3(m, 3H); 2.14(m, 1H); 2.0-1.9(m, 4H); 1.55(m, 1H); 1.44(s, 9H); 1.33(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(MeOD) δ 171.99, 171.157, 171.027, 166.761, 142.554, 127.964, 127.759, 125.447, 77.899, 68.452, 59.114, 57.750, 51.573, 49.165, 40.875, 38.712, 38.401, 29.334, 28.611, 28.415, 28.266, 25.803, 22.953, 20.715, 19.348, 16.862, 16.797, 15.747, 15.235 12.314
Mass spec (MH ⁺)	738.3

5

Example 12

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 4-aminomethylpyridine as RNH₂ in step F.

Molecular Formula	C ₃₄ H ₅₈ N ₆ O ₇ S
Molecular Weight	694.94
Mass spec (MH ⁺)	695.2

10 **Example 13**

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 4-aminomethylbenzoxyacetate as RNH₂ in step F and then removal of the methyl ester according to step G. Methyl 4-aminomethylbenzoxyacetate was prepared according to the procedure provided in J. Med. Chem. 1998, Vol. 31, No. 10

Molecular Formula	C ₃₇ H ₆₁ N ₅ O ₁₀ S
Molecular Weight	767.99
H-nmr (solvent)	(MeOD): δ 7.25 (t, 1H), 6.98 (m, 2H), 6.77 (s, 2H), 4.77 (s, 2H), 4.44 (m, 1h), 4.32 (m, 1h), 3.8 (m, 3H), 3.33 (s, 2h), 2.4 (m, 5 H), 2.1 (m, 1H), 1.66 (m, 1h), 1.44 (s, 9h), 0.99 (m, 18H)

C-nmr (solvent)	(MeOD): δ 169.033, 168.178, 167.998, 167.873, 166.744, 153.686, 135.801, 124.671, 124.617, 120.227, 115.650, 108.690, 108.463, 74.839, 65.411, 59.815, 55.935, 53.802, 54.548, 54.344, 48.403, 48.074, 46.067, 35.651, 35.463, 35.322, 26.489, 26.144, 25.642, 25.501, 25.345, 25.078, 24.819, 22.711, 19.741, 17.664, 16.206, 13.729, 13.588, 12.593, 12.216, 9.246
Mass spec (MH ⁺)	768

Example 14

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 3-aminomethylbenzoate as RNH₂ in step F and then removal of the methyl ester

5 according to step G.

Molecular Formula	C ₃₆ H ₅₉ N ₅ O ₉ S
Molecular Weight	737.96
H-nmr (solvent)	(CD ₃ OD/CDCl ₃) δ 8.0(s, 1H); 7.89(d, 1H); 7.89(s, 1H); 7.66(s, 1H); 7.55(d, 1H); 7.50(d, 1H); 7.44(t, 1H); 6.88(d, 1H); 6.77(d, 1H); 4.6-4.4(m, 3H); 4.33(m, 1H); 4.0-3.8(m, 3H); 2.5-2.3(m, 4H); 2.22(m, 1H); 2.1-1.9(m, 5H); 1.5-1.4((m, 11H); 1.40(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(CD ₃ OD/CDCl ₃) δ 169.088, 168.123, 168.045, 139.924, 134.445, 126.984, 124.217, 123.684, 75.255, 56.053, 54.603, 48.685, 45.942, 35.698, 35.494, 29.444, 25.932, 25.650, 25.292, 25.227, 25.078, 24.106, 23.032, 19.866, 17.899, 16.527, 14.019, 12.859, 12.449, 12.271, 9.583
Mass spec (MH ⁺)	

Example 15

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 4-aminocyclohexylcarboxylate as RNH₂ in step F and then removal of the methyl

10 ester according to step G.

Molecular Formula	C ₃₅ H ₆₃ N ₅ O ₉ S
Molecular Weight	729.97
H-nmr (solvent)	(CD ₃ OD) δ 8.34(d, 1H); 8.11(d, 1H); 7.98(d, 1H); 7.55(d, 1H); 6.88(d, 1H); 4.55(m, 1H); 4.23(m, 1H); 3.9-3.8(m, 5H); 3.34(m, 1H); 2.6-2.5(m, 3H); 2.32(D, 2H); 2.0(S, 3H); 1.98(M, 2H); 1.67(m, 8H); 1.44(s, 9H); 1.33(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(CD ₃ OD) δ 172.991, 168.241, 168.163, 167.849, 167.222, 74.761, 65.419, 54.383, 48.191, 46.663, 35.463, 35.236, 34.726, 26.387, 25.870, 25.055, 24.091, 22.688, 20.258, 19.795, 17.671, 16.237, 13.753, 12.616, 12.428, 9.183
Mass spec (MH ⁺)	730.5

Example 16

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using 2-aminoglutaramide as RNH₂ in step F.

Molecular Formula	C ₃₃ H ₆₁ N ₇ O ₉ S
Molecular Weight	731.96
H-nmr (solvent)	(CD ₃ OD) δ 8.44(d, 1H); 8.22(d, 1H); 7.86(d, 1H); 6.88(m, 1H); 4.56(m, 1H); 4.33(m, 1H); 4.0-3.9(m, 3H); 3.33(m, 2H); 2.55(m, 2H); 2.43(m, 2H); 2.1-1.9(m, 5H); 1.55(m, 1H); 1.44(s, 9H); 1.33(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(CD ₃ OD) δ 174.129, 96.505, 80.711, 71.549, 61.971, 59.440, 59.283, 54.189, 52.786, 52.480, 41.437, 32.525, 31.640, 28.700, 25.785, 23.786, 22.211, 22.140, 19.781, 19.475, 18.621, 18.449, 15.235
Mass spec (MH ⁺)	731

5

Example 17

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 1-aminocyclopropane-1-carboxylate as RNH₂ in step F and then removal of the methyl ester according to step G.

Molecular Formula	C ₃₂ H ₅₇ N ₅ O ₉ S
Molecular Weight	687.90
Mass spec (MH ⁺)	688

10

Example 18

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using 3-amino-dihydro-2(3H)-furanone as RNH₂ in step F.

Molecular Formula	C ₃₂ H ₅₇ N ₅ O ₉ S
Molecular Weight	687.90
Mass spec (MH ⁺)	688.4

15

Example 19

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 4-aminobutan-1-ol as RNH₂ in step F.

Molecular Formula	C ₃₂ H ₆₁ N ₅ O ₈ S
Molecular Weight	675.92

H-nmr (solvent)	(CD ₃ OD) δ 8.33(m, 1H); 8.11(m, 1H); 4.55(m, 1H); 4.11(m, 1H); 4.0-3.9(m, 2H); 3.55(m, 2H); 3.33(m, 2H); 3.30(m, 2H); 2.55(m, 2H); 2.1-1.9(m, 4H); 1.66(m, 2H); 1.44(s, 9H); 1.33(m, 1H); 0.99(m, 18H)
Mass spec (MH ⁺)	676

Example 20

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 3-aminobenzoate as RNH₂ in step F and then removal of the methyl ester

- 5 according to step G.

Molecular Formula	C ₃₅ H ₅₇ N ₅ O ₉ S
Molecular Weight	723.94
Mass spec (MH ⁺)	724

Example 21

- 10 Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using methyl 4-piperidine-acetate as RNH₂ in step F and then removal of the methyl ester according to step G.

Molecular Formula	C ₃₅ H ₆₃ N ₅ O ₉ S
Molecular Weight	729.98
H-nmr (solvent)	(CD ₃ OD) δ 8.22(m, 1H); 7.66(m, 1H); 6.88(d, 1H); 4.87(m, 1H); 4.55(m, 1H); 4.0-3.8(m, 3H); 3.22(m, 2H); 2.6-2.3(m, 2H); 2.22(m, 2H); 2.15(m, 1H); 2.0-1.9(m, 5H); 1.77(m, 1H); 1.55(m, 1H); 1.44(m, 9H); 1.33(m, 1H); 0.99(18H)
C-nmr (solvent)	(CD ₃ OD) δ 173.964, 166.095, 126.225, 80.680, 71.447, 61.854, 61.854, 55.427, 54.165, 43.404, 42.283, 41.444, 41.045, 34.320, 33.646, 32.510, 31.890, 31.067, 30.824, 28.685, 25.785, 23.739, 22.179, 20.040, 19.765, 18.574, 18.425, 18.221, 15.227
Mass spec (MH ⁺)	730

Example 22

- 15 Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using ethyl piperazine-N¹-carboxylate as RNH₂ in step F and then removal of the ethyl ester according to step G.

Molecular Formula	C ₃₅ H ₆₄ N ₆ O ₉ S
Molecular Weight	744.98

H-nmr (solvent)	(CD ₃ OD) δ 7.55(d, 1H); 4.66(d, 2H); 4.55(m, 1H); 4.12(m, 2H); 4.1-3.8(m, 4H); 3.5-3.2(m, 4H); 2.55(m, 2H); 2.20(m, 2H); 2.1-1.90(m, 5H); 1.66(m, 1H); 1.411(s, 9H); 1.33(m, 4H); 0.99(m, 18H)
C-nmr (solvent)	(CD ₃ OD) δ 174.873, 174.011, 173.925, 173.847, 172.592, 157.231, 80.688, 71.455, 62.967, 61.791, 55.631, 54.126, 52.942, 49.878, 49.306, 49.024, 46.837, 43.020, 41.382, 41.154, 32.619, 31.726, 31.107, 28.755, 23.802, 22.250, 19.820, 18.668, 18.558, 15.290, 14.883
Mass spec (MH ⁺)	745.4

Example 23

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using 1-acetamido-2-aminoethane as RNH₂ in step F.

5

Molecular Formula	C ₃₂ H ₆₀ N ₆ O ₈ S
Molecular Weight	688.93
H-nmr (solvent)	(MeOD): δ 8.33 (m, 2H), 8.01 (d, 1H), 7.66 (d, 1h), 6.88 (d, 1h), 4.56 (m, 1H), 4.22 (m, 1H), 3.8 (m, 3h), 3.44 (m, 2H), 2.56 (m, 2H), 2.33 (d, 2H), 2.2 (m, 8H), 1.66 (m, 1H), 1.44 (s, 9H), 1.33 (m, 1H), 0.99 (m, 18H)
C-nmr (solvent)	(MeOD): δ 194.616, 174.466, 155.044, 96.512, 76.275, 60.764, 54.400, 52.182, 41.562, 41.280, 39.916, 32.345, 31.579, 31.248, 31.154, 28.693, 25.816, 23.637, 22.650, 22.281, 19.750, 19.632, 18.613, 18.143, 15.204
Mass spec (MH ⁺)	689

Example 24

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using 1-amino 4-fluorobenzene as RNH₂ in step F.

10

Molecular Formula	C ₃₄ H ₅₆ N ₅ O ₇ S
Molecular Weight	697.91
H-nmr (solvent)	(MeOD): δ 7.66 (m, 1H), 7.00 (m, 1H), 4.55 (m, 1H), 4.34 (m, 1H), 4.22 (d, 2H), 4.0 (m, 4H), 3.22 (s, 9H), 2.66 (m, 2H), 2.45 (m, 2H), 1.9 (m, 5H), 1.66 (m, 1H), 1.44 (s, 9H), 1.33 (m, 1H), 0.99 (18H)
Mass spec (MH ⁺)	699

Example 25

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using 4-aminomethylbenzocarboxamide as RNH₂ in step F.

15

Molecular Formula	C ₃₆ H ₆₀ N ₆ O ₈ S
Molecular Weight	736.98
H-nmr (solvent)	(CD ₃ OD) δ 8.22(d, 1H); 7.67(d, 2H); 7.44(d, 2H); 4.55(m, 1H); 4.0-3.90(m, 2H); 3.22(m, 2H); 3.10(m, 4H); 2.5-2.4(m, 3H); 2.01(d, 3H); 1.66(m, 1H); 1.44(s, 9H); 0.99(m, 18H)
C-nmr (solvent)	(CD ₃ OD) δ 169.174; 168.539; 168.48; 168.312; 168.139; 168.053; 166.211; 152.479; 138.481; 138.317; 127.665; 123.010; 122.971; 122.602; 122.555; 74.855; 65.419; 56.084; 54.673; 54.446; 48.238; 48.238; 46.640; 45.958; 37.548; 35.541; 35.541; 35.267; 35.157; 26.644; 25.486; 25.282; 25.109; 22.672; 19.788; 17.601; 16.073; 13.659; 12.616; 12.240; 9.144; 3.054
Mass spec (MH ⁺)	737.4

Example 26

Steps A through F were employed, selecting L-Met as AA₁ and L-Val as AA₂ and using 3,5-dicarboxycyclohexylamine as RNH₂ in step F. The amine was prepared as follows:

- 5 To 2.5 g of dimethyl 5-aminoisophthalate in 40 ml of methanol/4.8ml acetic acid (12%v/v) was added 1.25 g of 5% rhodium on alumina(50% w/w), the mixed slurry was saturated with hydrogen at 55 PSI and shaken for a total of 72 hrs. Upon completion of the hydrogenation the reaction was filtered through Celite and dried over anhydrous sodium sulfate. Filtration and subsequent rotoevaporation yielded 3.85g of crude product, which was then subjected to silica
- 10 gel chromatographic purification to afford 0.76g of Di-Methyl 1-Aminocyclohexyl-3, 5-Di-Carboxylate as a pale white solid. See also: Fieser & Fieser, Reagents for Org. Syn. 4, 418 and Freifelder, M.; Ng, Y. H.; Helgren, P. F.; *J. Org. Chem.*, **30**, 2485-6.

Molecular Formula	C ₃₆ H ₆₃ N ₅ O ₁₁ S
Molecular Weight	773
tlc Rf (solvent)	Rf=0.05 (10%MeOH/DCM)
Purification:	1. Acid/Base Washes. 2. Trituration w/ Ether/Filtration
Mass spec (MH ⁺)	772.3(ESI Neg.)
Synthetic Route Description	Method A, B, E, J, F, G Method J: Amino-Aryl Diesters to Amino-Cyclohexyl Diesters

Example 27

- 15 Prepared in a manner similar to Example 26, except that dimethyl 6-aminoterephthalate was utilized in the preparation of 2,5-dicarboxycyclohexylamine.

Molecular Formula	C ₃₆ H ₆₃ N ₅ O ₁₁ S
Molecular Weight	773
tlc Rf (solvent)	Rf=0.25 (10%MeOH/DCM)
Purification:	1. Acid/Base Washes. 2. Trituration w/ Ether/Filtration

Mass spec (MH ⁺)	774.4(ESI -Positive)
Elemental Analysis-Calc (%)	
Found (%)	
Synthetic Route Description	Method A, B, E, J, F, G Method J: Amino-Aryl Diesters to Amino-Cyclohexyl Diesters

Example 28

Prepared using methyl 4-aminoocyclohexylacetate.

Molecular Formula	C ₃₆ H ₆₅ N ₅ O ₉ S
Molecular Weight	744
H-nmr (solvent)	(MeOD) δ 8.32(d, 1H); 8.00(d, 1H); 7.66(d, 1H); 4.66(m, 1H); 4.20(d, 2H); 4.0-3.88(m, 3H); 3.46(m, 2H); 2.66(m, 1H); 2.40(d, 2H); 2.30(d, 2H); 2.1-1.90(m, 4H); 1.77(m, 4H); 1.44(s, 9H); 1.33(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(MeOD) δ 177.003, 175.060, 174.197, 173.915, 173.194, 80.785, 71.427, 61.927, 60.422, 54.293, 52.631, 41.486, 41.204, 40.200, 33.256, 32.645, 32.598, 32.347, 31.845, 31.720, 31.594, 31.108, 29.509, 28.788, 28.710, 25.841, 23.678, 22.283, 19.775, 19.665, 18.615, 18.53, 15.197
Mass spec (MH ⁺)	744
Synthetic Route Description	Method F, J, G

5

Example 29

Prepared according to the initial preparation used to prepare Example 11 but Steps M and N are inserted prior to the removal of the ester alcohol. Aminomethylbenzoic acid was first protected with 1 equivalent of BOC and then the N-protected amine was methylated with methyl iodide. The BOC group was subsequently removed and the N-methyl-aminomethylbenzoic acid was coupled with the tetrapeptide.

10

Molecular Formula	C ₃₇ H ₆₁ N ₅ O ₉ S
Molecular Weight	751.97
H-nmr (solvent)	(MeOD) δ 8.10(m, 2H); 7.45(m, 2H); 4.66(m, 5H); 4.0-3.80(m, 4H); 3.20(m, 2H); 2.90(m, 3H); 2.60(m, 1H); 2.40(m, 2H); 2.2-2.0(m, 4H); 1.66(m, 1H); 1.44(s, 9H); 1.33(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(MeOD) δ 174.934, 174.448, 174.244, 174.041, 173.947, 169.714, 143.865, 131.418, 131.136, 128.816, 80.738, 71.583, 61.896, 61.770, 56.190, 55.939, 54.152, 53.039, 52.098, 49.857, 41.470, 36.078, 36.046, 32.519, 32.018, 31.093, 28.694, 25.810, 23.709, 22.173, 19.775, 19.634, 18.615, 18.427, 15.229
Mass spec (MH ⁺)	752

Synthetic Route Description	Method F, M,N,G
-----------------------------	-----------------

Example 30

The amine utilized was dimethyl 1-amino-1,3-propane-dicarboxylate and then the dicarboxylate was saponified to provide the dicarboxylic acid.

5

Molecular Formula	C ₃₃ H ₅₉ N ₅ O ₁₁ S
Molecular Weight	733.91
H-nmr (solvent)	(MeOD) δ 8.45(d, 1H); 8.25(d, 1H); 7.60(d, 1H); 4.55(m, 1H); 4.25(d, 2H); 4.01-3.80(m, 3H); 3.40(m, 2H); 2.60(m, 1H); 2.60(m, 1H); 2.40(m, 2H); 2.2-1.9(m, 4H); 1.66(m, 1H); 1.44(s, 9H); 1.33(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(MeOD) δ 176.627, 175.012, 174.809, 174.244, 174.197, 173.978, 80.769, 71.505, 61.880, 60.218, 54.230, 52.913, 52.678, 41.517, 41.219, 32.409, 31.688, 31.234, 31.077, 28.694, 27.644, 25.826, 23.741, 22.252, 19.759, 19.665, 18.615, 18.474, 15.213
Mass spec (MH ⁺)	734
Synthetic Route Description	Method F, G

Example 31

The tetrapeptide was coupled to the N-terminal capping group. The capping groups was prepared by reacting 1-bromo-1-(4-benzoic acid) ethane with sodium azide, reducing the resulting azide to the amine and coupling the product with the tetrapeptide.

10

Molecular Formula	C ₃₇ H ₆₁ N ₅ O ₉ S
Molecular Weight	751.97
H-nmr (solvent)	(MeOD / CCl ₃ D) δ 7.98(d, 2H); 7.36(m, 2H); 5.03(m, 1H); 4.66(m, 1H); 4.32(m, 2H); 4.0-3.9(m, 2H); 2.56(m, 1H); 2.1-1.9(m, 7H); 1.66(m, 1H); 1.44(s, 9H); 1.33(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(MeOD / CCl ₃ D) δ 174.244, 173.931, 132.562, 130.885, 130.039, 126.997, 71.536, 69.185, 41.517, 41.298, 40.106, 31.563, 30.089, 28.835, 25.888, 24.885, 24.007, 23.709, 22.424, 22.346, 19.822, 18.677, 15.339, 14.461, 11.435
Mass spec (MH ⁺)	752
Synthetic Route Description	Method F, K, L, G

Example 32

Prepared in a manner similar to Example 26, except that dimethyl 5-aminophthalate was utilized in the preparation of 3,4-dicarboxycyclohexylamine.

15

Molecular Formula	C ₃₆ H ₆₃ N ₅ O ₁₁ S
-------------------	--

Molecular Weight	773
tlc Rf (solvent)	Rf=0.19 (10%MeOH/DCM)
Purification:	1. Acid/Base Washes. 2. Trituration w/ Ether/Filtration
Mass spec (MH ⁺)	774.5(ESI -Positive)
Synthetic Route Description	Method A, B, E, J, F, G Method J: Amino-Aryl Diesters to Amino-Cyclohexyl Diesters

Example 33

The tetrapeptide was coupled with 1-amino-indan-2-ol using step F.

Molecular Formula	C ₃₇ H ₆₁ N ₅ O ₈ S
Molecular Weight	736
H-nmr (solvent)	(MeOD) δ 7.99(m, 1H); 7.66(m, 1H); 7.4-7.2(b, 4H); 6.88(m, 1H); 5.33(b, 2H); 4.66(b, 1H); 4.50(m, 2H); 4.1-3.9(m, 3H); 3.33(b, 2H); 3.10(m, 1H); 3.0-2.9(m, 1H); 2.6-2.4(m, 2H); 2.22(m, 1H); 2.0-1.9(m, 4H); 1.44(s, 10H); 0.99(m, 18H)
C-nmr (solvent)	(MeOD) δ 168.484, 135.887, 123.057, 121.975, 120.274, 119.577, 68.060, 65.317, 55.747, 54.650, 52.753, 48.466, 46.906, 35.487, 35.150, 34.844, 26.340, 25.454, 25.031, 22.688, 19.788, 17.656, 16.229, 13.808, 12.577, 12.412, 9.207
Mass spec (MH ⁺)	736
Synthetic Route Description	Method F,

5

Example 34

The methyl ester of 2-carboxy-cyclohexylamine was prepared according to setp H, then coupled with the tetrapeptide and the free carboxylic acid was generated according to step G.

10

Molecular Formula	C ₃₆ H ₆₃ N ₆ O ₉ S
Molecular Weight	730
H-nmr (solvent)	(MeOD) δ 8.35(m, 1H); 8.25(m, 1H); 7.65(m, 1H); 6.80(m, 1H); 4.65(m, 1H); 4.20(m, 2H); 4.0-3.90(m, 3H); 3.35(m, 1H); 2.6-2.40(m, 3H); 2.20(b,s, 2H); 1.77(m, 2H); 1.66(m, 2H); 1.44(s, (H); 1.33(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(MeOD) δ 172.991, 172.912, 168.163, 167.073, 74.785, 65.434, 54.509, 48.348, 46.381, 35.353, 29.953, 26.959, 26.849, 26.418, 25.109, 23.424, 23.354, 22.735, 19.286, 17.711, 16.433, 16.355, 13.808, 13.666, 12.663, 12.358, 9.238
Synthetic Route Description	Method H, F, G

Example 35

The tetrapeptide was coupled with the methyl ester of phenylglycine and the ester group was subsequently removed.

Molecular Formula	C ₃₆ H ₅₉ N ₅ O ₉ S
Molecular Weight	737
H-nmr (solvent)	(MeOD) δ 7.44-7.30(m, 5H); 5.40(s, 1H); 4.55(m, 1H); 4.01(m, 2H); 3.98(m, 1H); 3.22(s, 2H); 2.44(m, 2H); 2.1-2.0(m, 5H); 1.66(m, 1H); 1.33(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(MeOD) δ 177.058, 123.794, 123.331, 122.924, 19.764, 17.679, 16.159, 13.729, 13.627, 12.553
Mass spec (MH ⁺)	738
Synthetic Route Description	Method F, G

5 **Example 36**

The tetrapeptide was coupled with 2-(5-(2-hydroxynitrobenzene))-1-ethanamine.

Molecular Formula	C ₃₆ H ₆₀ N ₆ O ₁₀ S
Molecular Weight	768.98
H-nmr (solvent)	(MeOD) δ 8.00(s, 1H); 7.66(d, 1H); 7.10(d, 1H); 4.55(m, 1H); 4.0-3.90(m, 3H); 3.55(M, 2H); 3.40(S, 2H); 2.80(m, 2H); 2.6-2.50(m, 2H); 2.40(m, 1H); 2.1-1.90(m, 4H); 1.60(m, 1H); 1.44(s, 9H); 1.30(m, 1H); 0.99(m, 18H)
C-nmr (solvent)	(MeOD) δ 169.174, 168.139, 168.037, 167.912, 152.479, 133.066, 129.562, 126.741, 120.079, 120.00, 115.133, 74.863, 65.897, 56.076, 54.634, 54.289, 48.513, 48.262, 46.663, 46.052, 35.283, 29.052, 29.005, 26.254, 25.486, 25.298, 25.486, 25.298, 25.172, 25.109, 22.680, 19.835, 17.711, 17.640, 16.253, 16.088, 13.596, 12.546, 12.075, 9.199
Mass spec (MH ⁺)	769
Synthetic Route Description	Method F

Example 37

10

The compound was prepared in a manner similar to Example 11 with the following variations: Phenyl-statine (Phe-Sta) was employed in place of statine and phenylglycine (Phg) was selected as AA₁ and N-Ac-L-Val was used as AA₂

Molecular Formula	C ₃₉ H ₄₉ N ₅ O ₈
Molecular Weight	715
Mass spec (MH ⁺)	716.3(APCI)

15

Example 38

The compound was prepared in a manner similar to Example 11 with the following variations: Phenylglycine (Phg) was selected as AA₁ and carbobenzyloxy (Cbz)-L-Val was selected as AA₂.

Molecular Formula	C ₄₂ H ₅₄ N ₅ O ₉
Molecular Weight	772.92
H-nmr (solvent)	(DMSO): δ 8.635 (m, 1H), 8.461(m, 1H), 7.899 (d, 2H), 7.399 (m, 10H), 5.571 (m, 1H), 4.982 (m, 2H), 4.335 (m, 2H), 4.157 (m, 1H), 3.833 (m, 1H), 2.317 (d, 1H), 1.999 (m, 3H), 1.335 (m, 1H), 1.141 (m, 1H), 0.808 (m, 15H), 0.564 (d, 1H), 0.550 (d, 1H)
Mass spec (MH ⁺)	774

5

Example 39

The compound was prepared in a manner similar to Example 11 with the following variation:

Phenylglycine (Phg) was selected as AA₁.

Molecular Formula	C ₃₉ H ₅₇ N ₅ O ₉
Molecular Weight	739.90
H-nmr (solvent)	(MeOD): δ 8.88 (d, 1H), 8.66 (d, 1h), 8.44 (d, 1H), 7.99 (d, 2H), 7.66 (d, 1H), 7.5 (m, 6H), 5.55 (d, 1H), 4.55 (m, 1H), 4.34 (m, 2H), 3.8 (m, 3H), 3.55 (m, 1h), 3.44 (m, 2H), 2.55 (m, 2H), 2.2 (m, 2H), 1.55 (m, 1H), 1.44 (s, 9H), 1.33 (m, 1H), 0.99 (m, 18H)
C-nmr (solvent)	(MeOD): δ 168.210, 166.470, 139.696, 125.079, 124.734, 123.927 123.721, 123.574, 123.433, 123.229, 122.884, 122.743, 122.594, 122.524, 74.628, 69.724, 55.574, 53.035, 46.036, 37.846, 37.744, 35.543, 35.369, 26.136, 25.517, 24.843, 23.793, 22.719, 22.625, 19.803, 19.631, 17.622, 17.546, 16.190, 15.955, 13.698, 13.729, 12.546, 12.342
Mass spec (MH ⁺)	740

10

Enzyme Inhibition Assay**Purpose/Rationale:**

- 15 The MBP-C125 assay, determines relative inhibition of β-secretase cleavage of an MPB-C125 substrate by the compounds assayed. Human brain β-Secretase from the concentrated HiQ pool prepared 7/16/97 in 0.20% Triton is used in the assay. Inhibition data was obtained from an ELISA which uses an anti-MBP capture antibody (on precoated and blocked 96-well high binding plates) followed by incubation with
- 20 diluted enzyme reaction supernatant, incubation with an anti-SW192 specific biotinylated reporter antibody and incubation with streptavidin/alkaline phosphatase. Detection was

effected by a fluorescent substrate signal on cleavage by the phosphatase. The ELISA only detected cleavage following Leu 596 at the substrate's Swedish APP 751 mutation site.

Compounds were diluted in a 1:1 dilution series to a six-point concentration curve (two wells per concentration) which took up one 96-plate row per compound tested. Relative compound inhibition potency was determined by calculating the concentration of compound that showed a fifty- percent reduction in detected signal compared to the enzyme reaction signal in the control wells with no added compound.

Procedure:

Each of the test compounds was weighed out into a vial and DMSO was added to make up a 10mM solution. To obtain a final compound concentration of 200 μ M at the high point of a 6-point dilution curve, 100 μ L of the 10 mM solution was added to well C1 of a 96-well V-bottom plate. Fifty μ L of DMSO was added to odd wells of row C across the plate and 1:1 serial dilutions were made. 10 μ L of each dilution was added to each of two wells on row C of a corresponding V-bottom plate to which 190 μ L of 52 mM NaOAc/7.9% DMSO, pH 4.5 were pre-added. The NaOAc diluted compound plate was spun down to pellet precipitant and 20 μ L/well was transferred to a corresponding flat-bottom plate to which 30 μ L of ice-cold enzyme-substrate mixture (2.5 μ L MBP-C125 substrate, 0.03 μ L enzyme and 24.5 ice cold 0.09% TX100 per 30 μ L) was added. The compound concentration in the final enzyme reaction was thus 50 times less than the starting concentration. The final reaction mixture of 200 μ M compound for the highest curve point was in 5% DMSO, 20 mM NaAc, 0.06% TX100, at pH 4.5. The enzyme reaction was started by warming the plates to 37° C. After 90 minutes at 37° C, 200 μ L/well cold specimen diluent was added to stop the reaction and 20 μ L/well was transferred to a corresponding α -MBP coated ELISA plate, containing 80 μ L/well specimen diluent. This reaction was incubated overnight at 4oC and the ELISA was developed the next day using a 2 hr. incubation with α -192SW followed by Streptavidin-AP conjugate and flourescent substrate. The signal was read on a fluorescent plate reader.

Methods for treating Alzheimer's disease and other diseases characterized by deposition of A β peptide.

This invention also relates to a method of treatment for patients suffering from disorders or diseases which can be attributed to A β plaque formation as previously described and, more specifically, a method of treatment involving the administration of the β -secretase inhibitors of formula 1 as the active constituents.

5 Accordingly, the compounds of formula 1 can be used among other things in the treatment of Alzheimer's disease, and in diseases and indications resulting from the over-expression of A β -peptide such as found in certain genetic defect diseases such as plaque formation associated with Trisomy 21 (Down's Syndrome) and Hereditary Cerebral Hemorrhage
10 with Amyloidosis of the Dutch-Type (HCHWA-D).

As mentioned above, compounds of formula 1 are useful in medicine since they are active as inhibitors of β -secretase. Accordingly another aspect, this invention concerns:

15 a method of management (by which is meant treatment or prophylaxis) of disease or conditions mediated by β -secretase in mammals, in particular in humans, which method comprises administering to the mammal an effective, amount of a compound of formula 1 above, or a pharmaceutically acceptable salt or ester thereof; and

20 a compound of formula (I) for use in human or veterinary medicine, particularly in the management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by β -secretase; and

the use of a compound of formula (I) in the preparation of a composition for the
25 management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by β -secretase.

The disease or conditions referred to above include Alzheimer's disease, plaque formation associated with Trisomy 21 (Down's Syndrome) and Hereditary Cerebral
30 Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D).

For the treatment of diseases characterized by the overproduction and deposition of A β -peptide, the compounds of formula (I) may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing non-toxic
35 pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used

herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. The compounds may be administered in an amount from about 0.1 mg/kg/day to about 500 mg/kg/day. Preferred amounts for daily administration are from about 1 mg/ kg to about 50 mg/kg. It will be understood however, that the amount of the compound actually administered will be determined by a physician in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, and the like.

10 Formulation of pharmaceutical compositions

Compositions are provided that contain therapeutically effective amounts of the compounds of formula 1. The compounds are preferably formulated into suitable pharmaceutical preparations such as tablets, capsules or elixirs, for oral administration or in sterile solutions or suspensions for parenteral administration. Typically the compounds described above are formulated into pharmaceutical compositions using techniques and procedures well known in the art.

About 1 to 500 mg of a compound or mixture of compounds for Formula 1 or a physiologically acceptable salt or ester is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in those compositions or preparations is such that a suitable dosage in the range indicated is obtained. The compositions are preferably formulated in a unit dosage form, each dosage containing from about 2 to about 100 mg, more preferably about 10 to about 30 mg of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Preferably, the compound of formula I above is employed at no more than about 20 weight percent of the pharmaceutical composition, more preferably no more than about 15 weight percent, with the balance being pharmaceutically inert carrier(s).

To prepare compositions, one or more compounds of formula 1 are mixed with a suitable pharmaceutically acceptable carrier. Upon mixing or addition of the compound(s), the resulting mixture may be a solution, suspension, emulsion or the like. Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for ameliorating the symptoms of the disease, disorder or condition treated and may be empirically determined.

Pharmaceutical carriers or vehicles suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration. In addition, the active materials can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action or have other action. The compounds may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients.

In instances in which the compounds exhibit insufficient solubility, methods for solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as Tween®, or dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as salts of the compounds or prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.

The concentrations of the compounds are effective for delivery of an amount, upon administration, that ameliorates the symptoms of the disorder for which the compounds are administered. Typically, the compositions are formulated for single dosage administration.

The compounds of formula 1 may be prepared with carriers that protect them against rapid elimination from the body, such as time release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to,

microencapsulated delivery systems, The active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective concentration may be determined empirically by testing the compounds in known in vitro and in vivo model systems for the treated disorder.

The compositions can be enclosed in ampoules, disposable syringes or multiple or single dose vials made of glass, plastic or other suitable material. Such enclosed compositions can be provided in kits.

10

The concentration of active compound in the drug composition will depend on absorption, inactivation and excretion rates of the active compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art.

15 The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

25

If oral administration is desired, the compound should be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition may also be formulated in combination with an antacid or other such ingredient.

30

Oral compositions will generally include an inert diluent or an edible carrier and may be compressed into tablets or enclosed in gelatin capsules. For the purpose of oral therapeutic administration, the active compound or compounds can be incorporated with excipients and used in the form of tablets, capsules or troches. Pharmaceutically
5 compatible binding agents and adjuvant materials can be included as part of the composition.

The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder, such as, but not limited to, gum
10 tragacanth, acacia, corn starch or gelatin; an excipient such as microcrystalline cellulose, starch and lactose, a disintegrating agent such as, but not limited to, alginic acid and corn starch; a lubricant such as, but not limited to, magnesium stearate; a gildant, such as, but not limited to, colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; and a flavoring agent such as peppermint, methyl salicylate, and fruit flavoring.

15 When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents. The compounds can also be administered as a
20 component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.

The active materials can also be mixed with other active materials which do not impair
25 the desired action, or with materials that supplement the desired action.

Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include any of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, a naturally occurring vegetable oil like sesame oil,
30 coconut oil, peanut oil, cottonseed oil, etc. or a synthetic fatty vehicle like ethyl oleate or the like, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic

acid (EDTA); buffers, such as acetates, citrates and phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose. Parenteral preparations can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass, plastic or other suitable material. Buffers, preservatives, antioxidants and the like can be
5 incorporated as required.


- If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropyleneglycol and mixtures thereof.
- 10 Liposomal suspensions, including tissue-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. For example, liposome formulations may be prepared as described in U.S. Pat. No. 4,522,811.
- 15 The active compounds may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters,
20 polylactic acid and others. Methods for preparation of such formulations are known to those skilled in the art.

While this invention has been described with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereby and should
25 only be construed by interpretation of the scope of the appended claims.

Claims

We claim:

1) A compound of formula 1



5




Formula 1

wherein

A is a straight or branched chain alkanoxy or alkenoxy of 1 to 5 carbon atoms, aryl, arylalkyl, the aryl being optionally substituted with 1 to 2 carbon atoms or halogen, adamantyloxy, or 4-aminobutanoic acid;

10

B is selected from the group consisting of hydroxy,



wherein a dithered line represents a point of attachment at B of formula 1;

D is H or an oxo group;

L is a 5 or 6 membered saturated, unsaturated or aromatic heterocycle having from 1 to 3 heteroatoms chosen from nitrogen, oxygen and sulfur, or a saturated, unsaturated or aromatic carbocycle of 3 to 6 carbon atoms, any group represented by L having optional substitution with R', OR', or halogen;

- 5 Q is a bond, or is a straight chain linking group of 1 to 3 non-hydrogen atoms chosen from the group consisting of -CH₂-, -O-, and -NH- wherein O and N may not be adjacent;

ring M is a stable 5 to 7-membered saturated, unsaturated or aromatic heterocycle having up to 2 additional N atoms and optionally having 1 to 2 atoms of O and S,

- 10 T is independently selected from the group consisting of H, OH, NO₂, C(O)N(R)₂, F, C₁-C₃ alkoxy, hydroxymethyl and CF₃, wherein at least one T is other than H;

x is an integer of 1 to 3,

y is an integer of 1 to 6,

z is 0 (zero), 1 or 2,

- 15 R' is independently H, -OH, C₁-C₂ alkyl or phenyl,

R is independently H, C₁-C₄ alkyl, or phenyl,

and E is H, or C₁-C₂ alkyl;

R₁ is C₁-C₅ alkyl;

R₂ is 2-propyl, 1-(2-methylpropyl)- or phenyl optionally substituted with R', OR' or

- 20 halogen;

R₃ is phenyl, C₁-C₅ alkyl, or 1-(2-methylthio-)ethyl-;

R₄ is 2-propyl, 2-butyl or 2-methylpropyl;

and stereoisomers, hydrates and pharmaceutically acceptable salts and esters thereof.

- 25 2) The compound of claim 1 wherein B is the group (i) wherein L is cyclohexane, x=0, z=0 or 1, Q is -CH₂- or a bond and E and R' are both H and R is H or C₁-C₅ alkyl.

3) The compound of claim 2 wherein B is selected from the group consisting of 3,5-dicarboxycyclohexylamine, 3,4-dicarboxycyclohexylamine and 2,4-dicarboxycyclo-

- 30 hexylamine and 2,5-dicarboxycyclohexylamine.

4) The compound of claim 1 wherein B is the group (i) wherein L is phenyl, x=1, z=0, Q is selected from a bond, -CH₂- and -O-CH₂-, R' is H and E is H or CH₃, and R is H or C₁-C₅ alkyl.

- 5) The compound of claim 4 wherein B is selected from the group consisting of 4-aminomethylbenzoic acid; 4-methylaminomethylbenzoic acid; 1-amino-1-(4-carboxyphenyl)ethane; 2-aminomethylbenzoxyacetic acid; 2-aminobenzoic acid and 4-aminobenzoic acid.
- 6) The compound of claim 1 wherein B is the group (ii) wherein y is from 2 to 6 inclusive, z = 0 or 1 and R' and E are both H and R is H or C₁₋₅ alkyl.
- 7) The compound of claim 6 wherein B is selected from the group consisting of 4-aminobutanoic acid- 3-aminopropanoic acid and glutamic acid.
- 8) The compound of claim 1 wherein B is the group (v) wherein x = 1 and z = 0.
- 9) The compound of claim 8 wherein B is selected from the group consisting of 3-aminofuran-2-one and 2-aminopentanedioic acid anhydride.
- 10) The compound of claim 1 wherein B is the group (v) wherein ring M is a 6-membered heterocycle having 1 to 2 atoms of N, z = 0, Q is a bond or CH₂ and R is H or C_{1-C5} alkyl.
- 11) The compound of claim 10 wherein B is selected from the group consisting of 4-piperidineacetic acid and piperazine-4-carboxylic acid.
- 12) The compound of claim 1 wherein B is the group (iv) wherein L is phenyl and T is selected from the group consisting of H, OH, F, NO₂, C(O)NH₂, C_{1-C2} alkoxy and hydroxymethyl.
- 13) The compound of claim 12 wherein B is selected from the group consisting of 1-amino-2-(3-nitro-4-hydroxyphenyl)ethane, 4-fluorobenzenamine, and aminomethylbenzene-4-carboxamide.

14) The compound of claim 1 wherein B is selected from 2-aminomethylthiazole-5-carboxylic acid and phenylglycine.

15) The compound of claim 1 wherein B is selected from 3,5- dimethoxycyclohexylamine, 3,5-dihydroxymethylcyclohexylamine and 3,4,5-trimethoxycyclohexylamine.

16) The compound of claim 1 wherein R₁ is 2-propyl and R₂ is chosen from the group consisting of 2-methylpropyl and benzyl.

10

17) The compound of claim 16 wherein B is the group (i) wherein L is cyclohexane, x=0, z= 0 or 1, Q is -CH₂- or a bond and E and R' are both H and R is H or C₁-C₅ alkyl.

15

18) The compound of claim 17 wherein B is selected from the group consisting of 3,5-dicarboxycyclohexylamine, 3,4-dicarboxycyclohexylamine and 2,4-dicarboxycyclohexylamine and 2,5-dicarboxycyclohexylamine.

20

19) The compound of claim 16 wherein B is selected from the group consisting of 4-aminomethylbenzoic acid, 4-methylaminomethylbenzoic acid 1-amino-1-(4-carboxyphenyl)ethane, 2-aminomethylbenzoxyacetic acid, 2-aminobenzoic acid and 4-aminobenzoic acid.

25

20) The compound of claim 16 wherein B is selected from the group consisting of 4-aminobutanoic acid- 3-aminopropionic acid and glutamic acid.

21) The compound of claim 16 wherein B is selected from the group consisting of 3-aminofuran-2-one and 2-aminopentanedioic acid anhydride.

30

22) The compound of claim 16 wherein B is selected from the group consisting of 4-piperidineacetic acid and piperazine-4-carboxylic acid.


23) The compound of claim 16 wherein B is selected from the group consisting of 1-amino-2-(3-nitro-4-hydroxyphenyl)ethane, 4-fluorobenzenamine, and aminomethylbenzene-4-carboxamide.

- 24) The compound of claim 16 wherein B is selected from 2-aminomethylthiazole-5-carboxylic acid and phenylglycine.
- 5 25) The compound of claim 16 wherein B is selected from 3,5- dimethoxycyclohexylamine, 3,5-dihydroxymethylcyclohexylamine and 3,4,5-trimethoxycyclohexylamine.
- 26) The compound of claim 1 wherein R₃ is selected from the group consisting of phenyl
10 and 2-methylthioethyl and R₄ is 2-propyl.
- 27) The compound of claim 16 wherein R₃ is selected from the group consisting of phenyl and 2-methylthioethyl and R₄ is 2-propyl.
- 15 28) The compound of claim 17 wherein R₃ is selected from the group consisting of phenyl and 2-methylthioethyl and R₄ is 2-propyl.
- 29) The compound of claim 18 wherein R₃ is selected from the group consisting of phenyl and 2-methylthioethyl and R₄ is 2-propyl.
- 20 30) The compound of claim 19 wherein R₃ is selected from the group consisting of phenyl and 2-methylthioethyl and R₄ is 2-propyl.
- 31) The compound of claim 20 wherein R₃ is selected from the group consisting of
25 phenyl and 2-methylthioethyl and R₄ is 2-propyl.
- 32) The compound of claim 21 wherein R₃ is selected from the group consisting of phenyl and 2-methylthioethyl and R₄ is 2-propyl.
- 30 33) The compound of claim 22 wherein R₃ is selected from the group consisting of phenyl and 2-methylthioethyl and R₄ is 2-propyl.
- 34) The compound of claim 23 wherein R₃ is selected from the group consisting of phenyl and 2-methylthioethyl and R₄ is 2-propyl.
- 35 35) The compound of claim 24 wherein R₃ is selected from the group consisting of phenyl and 2-methylthioethyl and R₄ is 2-propyl.

36) The compound of claim 25 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

5 37) The compound of claim 26 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

38) A method of slowing the progression of a disease state characterized by deposition of $A\beta$ peptide in a mammal comprising administering to a mammal in need thereof an
10 effective amount of a compound of Formula 1




Formula 1

wherein

A is a straight or branched chain alkanoxy or alkenoxy of 1 to 5 carbon atoms, aryl, arylalkyl, the aryl being optionally substituted with 1 to 2 carbon atoms or halogen, adamantyloxy, or 4-aminobutanoic acid;

B is selected from the group consisting of hydroxy,



- 5 wherein a dithere line represents a point of attachment at B of formula 1;
 D is H or an oxo group;
 L is a 5 or 6 membered saturated, unsaturated or aromatic heterocycle having from 1 to 3 heteroatoms chosen from nitrogen, oxygen and sulfur, or a saturated, unsaturated or aromatic carbocycle of 3 to 6 carbon atoms, any group represented by L having optional
 10 substitution with R', OR', or halogen;
 Q is a bond, or is a straight chain linking group of 1 to 3 non-hydrogen atoms chosen from the group consisting of -CH₂-, -O-, and -NH- wherein O and N may not be adjacent;
 ring M is a stable 5 to 7-membered saturated, unsaturated or aromatic heterocycle having
 15 up to 2 additional N atoms and optionally having 1 to 2 atoms of O and S,
 T is independently selected from the group consisting of H, OH, NO₂, C(O)N(R)₂, F, C₁-C₃ alkoxy, hydroxymethyl and CF₃, wherein at least one T is other than H;
 x is an integer of 1 to 3,

y is an integer of 1 to 6,

z is 0 (zero), 1 or 2,

R' is independently H, -OH, C₁-C₂ alkyl or phenyl,

R is independently H, C₁-C₄ alkyl, or phenyl,

5 and E is H, or C₁-C₂ alkyl;

R₁ is C₁-C₅ alkyl;

R₂ is 2-propyl, 1-(2-methylpropyl)- or phenyl optionally substituted with R', OR' or halogen;

R₃ is phenyl, C₁-C₅ alkyl, or 1-(2-methylthio-)ethyl;

10 R₄ is 2-propyl, 2-butyl or 2-methylpropyl;

and stereoisomers, hydrates and pharmaceutically acceptable salts and esters thereof.

39) The method of claim 38 wherein B is the group (i) wherein L is cyclohexane, x=0, z=0 or 1, Q is -CH₂- or a bond and E and R' are both H and R is H or C₁-C₅ alkyl.

15

40) The method of claim 39 wherein B is selected from the group consisting of 3,5-dicarboxycyclohexylamine, 3,4-dicarboxycyclohexylamine and 2,4-dicarboxycyclohexylamine and 2,5-dicarboxycyclohexylamine.

20

41) The method of claim 38 wherein B is the group (i) wherein L is phenyl, x=1, z=0, Q is selected from a bond, -CH₂- and -O-CH₂-, R' is H and E is H or CH₃, and R is H or C₁-C₅ alkyl.

25

42) The method of claim 41 wherein B is selected from the group consisting of 4-aminomethylbenzoic acid; 4-methylaminomethylbenzoic acid; 1-amino-1-(4-carboxyphenyl)ethane; 2-aminomethylbenzoxyacetic acid; 2-aminobenzoic acid and 4-aminobenzoic acid.

30

43) The method of claim 38 wherein B is the group (ii) wherein y is from 2 to 6 inclusive, z = 0 or 1 and R' and E are both H and R is H or C₁₋₅ alkyl.

44) The method of claim 43 wherein B is selected from the group consisting of 4-aminobutanoic acid- 3-aminopropanoic acid and glutamic acid.

45) The method of claim 38 wherein B is the group (v) wherein $x = 1$ and $z = 0$.

46) The method of claim 45 wherein B is selected from the group consisting of
5 3-aminofuran-2-one and 2-aminopentanedioic acid anhydride.

47) The method of claim 38 wherein B is the group (v) wherein ring M is a 6-membered heterocycle having 1 to 2 atoms of N, $z = 0$, Q is a bond or CH_2 and R is H or $\text{C}_1\text{-C}_5$ alkyl.

10

48) The method of claim 47 wherein B is selected from the group consisting of 4-piperidineacetic acid and piperazine-4-carboxylic acid.

49) The method of claim 38 wherein B is the group (iv) wherein L is phenyl and T is
15 selected from the group consisting of H, OH, F, NO_2 , C(O)NH_2 , $\text{C}_1\text{-C}_2$ alkoxy and hydroxymethyl.

50) The method of claim 49 wherein B is selected from the group consisting of 1-amino-2-(3-nitro-4-hydroxyphenyl)ethane, 4-fluorobenzenamine, and aminomethylbenzene-4-
20 carboxamide.

51) The method of claim 38 wherein B is selected from 2-aminomethylthiazole-5-carboxylic acid and phenylglycine.

25 52) The method of claim 38 wherein B is selected from 3,5- dimethoxycyclohexylamine, 3,5-dihydroxymethylcyclohexylamine and 3,4,5-trimethoxycyclohexylamine.

53) The method of claim 38 wherein R_1 is 2-propyl and R_2 is chosen from the group consisting of 2-methylpropyl and benzyl.

30

54) The method of claim 53 wherein B is the group (i) wherein L is cyclohexane, $x=0$, $z=0$ or 1, Q is $-\text{CH}_2-$ or a bond and E and R' are both H and R is H or $\text{C}_1\text{-C}_5$ alkyl.

- 55) The method of claim 54 wherein B is selected from the group consisting of 3,5-dicarboxycyclohexylamine, 3,4-dicarboxycyclohexylamine and 2,4-dicarboxycyclohexylamine and 2,5-dicarboxycyclohexylamine.
- 5 56) The method of claim 53 wherein B is selected from the group consisting of 4-aminomethylbenzoic acid, 4-methylaminomethylbenzoic acid 1-amino-1-(4-carboxyphenyl)ethane, 2-aminomethylbenzoxyacetic acid, 2-aminobenzoic acid and 4-aminobenzoic acid.
- 10 57) The method of claim 53 wherein B is selected from the group consisting of 4-aminobutanoic acid- 3-aminopropionic acid and glutamic acid.
- 58) The method of claim 53 wherein B is selected from the group consisting of 3-aminofuran-2-one and 2-aminopentanedioic acid anhydride.
- 15 59) The method of claim 53 wherein B is selected from the group consisting of 4-piperidineacetic acid and piperazine-4-carboxylic acid.
- 60) The method of claim 53 wherein B is selected from the group consisting of 1-amino-2-(3-nitro-4-hydroxyphenyl)ethane, 4-fluorobenzenamine, and aminomethylbenzene-4-carboxamide.
- 20 61) The method of claim 53 wherein B is selected from 2-aminomethylthiazole-5-carboxylic acid and phenylglycine.
- 25 62) The method of claim 53 wherein B is selected from 3,5- dimethoxycyclohexylamine, 3,5-dihydroxymethylcyclohexylamine and 3,4,5-trimethoxycyclohexylamine.
- 63) The method of claim 38 wherein R₃ is selected from the group consisting of phenyl and 2-methylthioethyl and R₄ is 2-propyl.
- 30 64) The method of claim 43 wherein R₃ is selected from the group consisting of phenyl and 2-methylthioethyl and R₄ is 2-propyl.

65) The method of claim 44 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

5 66) The method of claim 45 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

67) The method of claim 46 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

10 68) The method of claim 47 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

15 69) The method of claim 48 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

20 70) The method of claim 49 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.


71) The method of claim 50 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

72) The method of claim 51 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

25 73) The method of claim 52 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

74) The method of claim 53 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.




30 75) A pharmaceutical composition comprising a compound of formula 1



Formula 1

wherein

- 5 A is a straight or branched chain alkanoxy or alkenoxy of 1 to 5 carbon atoms, aryl, arylalkyl, the aryl being optionally substituted with 1 to 2 carbon atoms or halogen, adamantyloxy, or 4-aminobutanoic acid;
B is selected from the group consisting of hydroxy,



wherein a dithered line represents a point of attachment at B of formula 1;

- 10 D is H or an oxo group;
L is a 5 or 6 membered saturated, unsaturated or aromatic heterocycle having from 1 to 3 heteroatoms chosen from nitrogen, oxygen and sulfur, or a saturated, unsaturated or aromatic carbocycle of 3 to 6 carbon atoms, any group represented by L having optional substitution with R', OR', or halogen;

Table 1. Demographic characteristics of the study population	
Age (years)	
18-24	100 (10.0)
25-34	150 (15.0)
35-44	200 (20.0)
45-54	250 (25.0)
55-64	300 (30.0)
65-74	350 (35.0)
75-84	400 (40.0)
85-94	450 (45.0)
95-104	500 (50.0)
Gender	
Male	500 (50.0)
Female	500 (50.0)
Ethnicity	
White	300 (30.0)
Black	200 (20.0)
Hispanic	100 (10.0)
Asian	50 (5.0)
Other	50 (5.0)
Education level	
High school or less	100 (10.0)
Some college	150 (15.0)
Bachelor's degree	200 (20.0)
Master's degree	250 (25.0)
PhD	300 (30.0)
Postgraduate	350 (35.0)
Income level	
<\$10,000	100 (10.0)
\$10,000-\$20,000	150 (15.0)
\$20,000-\$30,000	200 (20.0)
\$30,000-\$40,000	250 (25.0)
\$40,000-\$50,000	300 (30.0)
\$50,000-\$60,000	350 (35.0)
\$60,000-\$70,000	400 (40.0)
\$70,000-\$80,000	450 (45.0)
\$80,000-\$90,000	500 (50.0)
\$90,000-\$100,000	550 (55.0)
\$100,000+	600 (60.0)
Marital status	
Married	300 (30.0)
Single	200 (20.0)
Divorced	100 (10.0)
Widowed	50 (5.0)
Other	50 (5.0)
Health insurance	
Medicare	300 (30.0)
Medicaid	200 (20.0)
Private	100 (10.0)
Other	50 (5.0)
Employment status	
Employed	300 (30.0)
Unemployed	200 (20.0)
Retired	100 (10.0)
Other	50 (5.0)
Living arrangement	
Alone	100 (10.0)
With family	150 (15.0)
With friends	200 (20.0)
With pets	250 (25.0)
With other	300 (30.0)
Health status	
Good	300 (30.0)
Fair	200 (20.0)
Poor	100 (10.0)
Very poor	50 (5.0)
Other	50 (5.0)

Q is a bond, or is a straight chain linking group of 1 to 3 non-hydrogen atoms chosen from the group consisting of $-\text{CH}_2-$, $-\text{O}-$, and $-\text{NH}-$ wherein O and N may not be adjacent;

ring M is a stable 5 to 7-membered saturated, unsaturated or aromatic heterocycle having

5 up to 2 additional N atoms and optionally having 1 to 2 atoms of O and S,

T is independently selected from the group consisting of H, OH, NO_2 , $\text{C}(\text{O})\text{N}(\text{R})_2$, F, C_1 - C_3 alkoxy, hydroxymethyl and CF_3 , wherein at least one T is other than H;

x is an integer of 1 to 3,

y is an integer of 1 to 6,

10 z is 0 (zero), 1 or 2,

R' is independently H, $-\text{OH}$, C_1 - C_2 alkyl or phenyl,

R is independently H, C_1 - C_4 alkyl, or phenyl,

and E is H, or C_1 - C_2 alkyl;

R₁ is C_1 - C_5 alkyl;

15 R₂ is 2-propyl, 1-(2-methylpropyl)- or phenyl optionally substituted with R', OR' or halogen;

R₃ is phenyl, C_1 - C_5 alkyl, or 1-(2-methylthio)ethyl-;

R₄ is 2-propyl, 2-butyl or 2-methylpropyl;

20 and hydrates, pharmaceutically acceptable salts and esters thereof and a pharmaceutically acceptable diluent.

76) The composition of claim 75 wherein B is the group (i) wherein L is cyclohexane, $x=0$, $z=0$ or 1, Q is $-\text{CH}_2-$ or a bond and E and R' are both H and R is H or C_1 - C_5 alkyl.

25 77) The composition of claim 76 wherein B is selected from the group consisting of 3,5-dicarboxycyclohexylamine, 3,4-dicarboxycyclohexylamine and 2,4-dicarboxycyclohexylamine and 2,5-dicarboxycyclohexylamine.

78) The composition of claim 75 wherein B is the group (i) wherein L is phenyl, $x=1$,

30 $z=0$,

Q is selected from a bond, $-\text{CH}_2-$ and $-\text{O}-\text{CH}_2-$, R' is H and E is H or CH_3 , and R is H or C_1 - C_5 alkyl.

79) The composition of claim 78 wherein B is selected from the group consisting of 4-aminomethylbenzoic acid; 4-methylaminomethylbenzoic acid; 1-amino-1-(4-carboxyphenyl)ethane; 2-aminomethylbenzoxyacetic acid; 2-aminobenzoic acid and 4-aminobenzoic acid.

5

80) The composition of claim 75 wherein B is the group (ii) wherein y is from 2 to 6 inclusive, z = 0 or 1 and R' and E are both H and R is H or C₁₋₅ alkyl.

10

81) The composition of claim 80 wherein B is selected from the group consisting of 4-aminobutanoic acid- 3-aminopropanoic acid and glutamic acid.

82) The composition of claim 75 wherein B is the group (v) wherein x = 1 and z = 0.

15

83) The composition of claim 82 wherein B is selected from the group consisting of 3-aminofuran-2-one and 2-aminopentanedioic acid anhydride.

20

84) The composition of claim 75 wherein B is the group (v) wherein ring M is a 6-membered heterocycle having 1 to 2 atoms of N, z = 0, Q is a bond or CH₂ and R is H or C₁-C₅ alkyl.

85) The composition of claim 85 wherein B is selected from the group consisting of 4-piperidineacetic acid and piperazine-4-carboxylic acid.

25

86) The composition of claim 75 wherein B is the group (iv) wherein L is phenyl and T is selected from the group consisting of H, OH, F, NO₂, C(O)NH₂, C₁-C₂ alkoxy and hydroxymethyl.

30

87) The composition of claim 86 wherein B is selected from the group consisting of 1-amino-2-(3-nitro-4-hydroxyphenyl)ethane, 4-fluorobenzenamine, and aminomethylbenzene-4-carboxamide.

88) The composition of claim 75 wherein B is selected from 2-aminomethylthiazole-5-carboxylic acid and phenylglycine.

89) The composition of claim 75 wherein B is selected from 3,5- dimethoxycyclohexylamine, 3,5-dihydroxymethylcyclohexylamine and 3,4,5-trimethoxycyclohexylamine.

90) The composition of claim 75 wherein R₁ is 2-propyl and R₂ is chosen from the group consisting of 2-methylpropyl and benzyl.

10

91) The composition of claim 90 wherein B is the group (i) wherein L is cyclohexane, x=0, z= 0 or 1, Q is -CH₂- or a bond and E and R' are both H and R is H or C₁-C₅ alkyl.

15

92) The composition of claim 91 wherein B is selected from the group consisting of 3,5-dicarboxycyclohexylamine, 3,4-dicarboxycyclohexylamine and 2,4-dicarboxycyclohexylamine and 2,5-dicarboxycyclohexylamine.

20

93) The composition of claim 90 wherein B is selected from the group consisting of 4-aminomethylbenzoic acid, 4-methylaminomethylbenzoic acid 1-amino-1-(4-carboxyphenyl)ethane, 2-aminomethylbenzoxyacetic acid, 2-aminobenzoic acid and 4-aminobenzoic acid.

25

94) The composition of claim 90 wherein B is selected from the group consisting of 4-aminobutanoic acid- 3-aminopropionic acid and glutamic acid.

95) The composition of claim 90 wherein B is selected from the group consisting of 3-aminofuran-2-one and 2-aminopentanedioic acid anhydride.

30

96) The composition of claim 90 wherein B is selected from the group consisting of 4-piperidineacetic acid and piperazine-4-carboxylic acid.

97) The composition of claim 90 wherein B is selected from the group consisting of 1-amino-2-(3-nitro-4-hydroxyphenyl)ethane, 4-fluorobenzenamine, and aminomethylbenzene-4-carboxamide.

98) The composition of claim 90 wherein B is selected from 2-aminomethylthiazole-5-carboxylic acid and phenylglycine.

5 99) The composition of claim 90 wherein B is selected from 3,5- dimethoxycyclohexylamine, 3,5-dihydroxymethylcyclohexylamine and 3,4,5-trimethoxycyclohexylamine.

100) The composition of claim 75 wherein R_3 is selected from the group consisting of
10 phenyl and 2-methylthioethyl and R_4 is 2-propyl.

101) The composition of claim 90 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

15 102) The composition of claim 91 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

103) The composition of claim 92 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

20 104) The composition of claim 93 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

25 105) The composition of claim 94 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

106) The composition of claim 95 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

30 107) The composition of claim 96 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

108) The composition of claim 97 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

35 109) The composition of claim 98 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

110) The composition of claim 99 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

- 5 111) The composition of claim 100 wherein R_3 is selected from the group consisting of phenyl and 2-methylthioethyl and R_4 is 2-propyl.

ABSTRACT

Statine-derived peptide inhibitors of the β -secretase enzyme are provided which are
5 useful in the treatment of Alzheimer's disease and other diseases characterized by
deposition of A β peptide in a mammal. The compounds of the invention provide useful
methods of treatment by administration of these inhibitors to reduce A β peptide formation
and pharmaceutical compositions.

09594657-061500

Please type a plus sign (+) inside this box \div ☐

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Attorney Docket Number	271-US-NEW	
	First Named Inventor	JOHN, Varghese	
	COMPLETE IF KNOWN		
	Application Number		
	Filing Date		
	Group Art Unit		
<input checked="" type="checkbox"/> Declaration Submitted with Initial Filing	OR	<input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)	
		Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

TETRAPEPTIDE INHIBITORS OF BETA-SECRETASE

the specification of which (Title of the Invention)

☒ is attached hereto
OR
☐ was filed on (MM/DD/YYYY) as United States Application Number or PCT International

Application Number and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 356(b) of any foreign application(s) for patent or inventor's certificate, or 356(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.
60/139,173	06/15/1999	

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00 OMB 0651-0032

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)



21835

PATENT AND TRADEMARK OFFICE

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet P

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact with the Patent and Trademark Office connected therewith:

☒ Customer Number 21835
OR
☐ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label ☒ Correspondence address below

Name	J. Mark Hoch				
Address	Elan Pharmaceuticals, Inc.				
Address	800 Gateway Boulevard				
City	South San Francisco	State	CA	ZIP	94080
Country		Telephone	650-616-5035	Fax	650-553-7165

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])		Family Name or Surname			
Varghese		JOHN			
Inventor's Signature				Date	
Residence: City	San Francisco	State	CA	Country	US
Post Office Address	1722 18th Street				
Post Office Address					
City	San Francisco	State	CA	ZIP	94122
		Country	US		

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-97)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page 1 of 1

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])				Family Name or Surname			
Jay				TUNG			
Inventor's Signature						Date	
Residence: City	Belmont	State	CA	Country	US	Citizenship	US
Post Office Address	2224 Semeria Avenue						
Post Office Address							
City	Belmont	State	CA	ZIP	94002	Country	US
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])				Family Name or Surname			
Lawrence				FANG			
Inventor's Signature						Date	
Residence: City	Foster City	State	CA	Country	US	Citizenship	US
Post Office Address	1193 Beach Park Blvd.						
Post Office Address							
City	Foster City	State	CA	ZIP	94404	Country	US
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])				Family Name or Surname			
Shumeye S.				MAMO			
Inventor's Signature						Date	
Residence: City	Oakland	State	CA	Country	US	Citizenship	US
Post Office Address	564 Oakland Avenue, #14						
Post Office Address							
City	Oakland	State	CA	ZIP	95611	Country	US

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.